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Abstract 
Alcohols are a common form of functionality in organic chemistry, and are often present 
in biologically active molecules.  The protection of hydroxy groups is crucial in long multi-step 
synthetic routes, as the unprotected alcohol is typically not compatible with many reagents.  
Alcohols are often protected as corresponding benzyl ether, which can then be removed when 
desired to reveal the alcohol functional group. Classic methodology for protection of alcohols as 
benzyl ethers requires harsh conditions utilizing strong acids and bases, which functions well for 
simple substrates. In more complex multifunctional molecules this can lead to degradation and 
side products.  Therefore, there is a need for the development of milder conditions for the 
protection of alcohols. 
Recently a number of reagents have been developed to form benzyl ethers under mild, 
neutral conditions that and do not disturb the sensitive functionality in complex molecules.  
Many of these reagents have been based on imidate-type systems. The most common imidate 
system, the trichloroacetimidate, is often utilized for the installation of ethers under Lewis acid 
catalyzed conditions.  Given their ready availability, a reevaluation of the reactivity of alcohols 
and trichloroacetimidates has been undertaken.  In many cases, simply heating the imidate with 
an alcohol in refluxing toluene without an exogenous acid or base is an effective method for the 
formation of the desired ether. This operationally simple procedure is most effective for 
trichloroacetimidates that are precursors to highly stabilized cations (i.e. the 4-methoxybenzyl 
and diphenylmethyl group). The use of this new procedure with a number of acid and base 
sensitive substrates, which are protected in excellent yield without disturbing the delicate 
functionality present in these molecules, is presented.  
Cancer is a group of disorders that are all defined by abnormal cell growth in an 
organism.  This is a very broad set of diseases that can affect multiple organs.  While classic 
cancer treatments have focused on killing all cells that divide quickly, more modern treatments 
attempt to selectively stop cancer progression by influencing cell signaling pathways. There are 
many studies about how cancer cells coopt cell signaling pathways and use these systems, which 
control cell growth in normal cells, to facilitate their own uncontrolled progression.  One of the 
major cell signaling pathways implicated in tumor development is the PI3K pathway, which is 
governed by the kinase PI3K and the phosphatases PTEN and SHIP. 
SHIP1 is an SH2-containing inositol 5’-phosphatase found in blood cells that is 
responsible for the hydrolysis of phosphatidylinositol-3,4,5-trisphosphate to 
phosphatidylinositol-4,5-bisphosphate.  This enzyme is part of a major cellular signaling 
pathway (the PI3K pathway) that controls many important cellular events such as proliferation, 
differentiation and adhesion.  SHIP1 inhibition has been found to increase blood cell production 
and slow the growth of blood cancer cells. Certain aminosteroids show selectivity as SHIP1 
inhibitors and therefore may have therapeutic applications.  In this study, syntheses of a number 
of aminosteroid derivatives were performed and these compounds are evaluated for their 
potential as SHIP1 inhibitors.   
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Chapter 1:  Formation of Ethers Under Mild Conditions 
Abstract: 
Alcohols are common in organic molecules, and are often present in biologically active 
natural products.  The protection of hydroxy groups is critical in long multi-step synthetic routes, 
as the unprotected alcohol is typically not compatible with many reagents.  Alcohols are often 
protected as benzyl ethers or substituted benzyl ethers, which can then be removed under a 
variety of conditions when desired. Classic protection methods for alcohols as benzyl ethers 
requires harsh conditions utilizing strong acids and bases, which functions well for simple 
substrates. In more complex polyfunctional molecules this can lead to degradation and side 
products.  Therefore, there is a need for the development of milder conditions for the protection 
of alcohols. Recently a number of reagents have been developed to form benzyl ethers under 
mild, neutral conditions that and do not disturb sensitive functionality.  This chapter provides 
details of many of these reagents and summarizes the conditions needed to install the ethers 
utilizing these new methods.   
Introduction: 
Ethers are of great value in organic synthesis since they can act as protecting groups for 
sensitive alcohols.1,2  Simple and mild conditions are often desired to protect and deprotect 
alcohol substrates as to minimize degradation of a multistep synthesis.  There are many known 
procedures to make ethers with the Williamson ether synthesis being a popular method.  Another 
classical method for ether synthesis is the Koenigs-Knorr reaction for glycoside formation.  Both 
methods employ the use of basic alkali metal alkoxides with alkyl halides.  Alternatively ethers 
may be formed from alcohols under acidic conditions. These methods can be problematic in the 
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protection of alcohols in complex molecules.  For example, carbohydrates can undergo base 
catalyzed migration of esters and silyl ethers.  Silyl ethers and acetal linkages could also be 
disturbed by acid catalyzed cleavage.  Metal catalysts have also been employed for the formation 
of ethers, however, they are usually expensive.3,4  Therefore, development of milder conditions 
for the protection of complex alcohols  so that other sensitive functionality is not disturbed in 
complex molecules is an ongoing area of research.    
Recently several different reagents have been advanced for the protection of alcohols in 
complex molecules without disturbing delicate functionality.  One often cited method is to use 
the trichloroacetimidate to form the ether in the presence of a Brønsted or Lewis acid. This 
methodology is especially useful for the introduction of benzyl, allyl, and 4-methoxybenzyl 
ethers.5,6,7 Other benzylic ethers have also been formed under these conditions. For example, the 
formation of DPM ethers have been reported with the use of trichloroacetimidates and Lewis 
acids (Figure 1.1).8,9  Diphenylmethyl trichloroacetimidate can be easily prepared with 
diphenylmethanol and trichloroacetonitrile and is stable at room temperature over long periods of 
time.  The facile formation of DPM ethers with DPM imidate in the presence of TMSOTf 
worked well on various primary and secondary alcohols.  This methodology was showcased in 
the creation of glycosidic bonds.  Because the diphenylmethyl group on an -alcohol at the 2-O 
position sterically hinders α bond formation, it facilitates stereoselective β-glucopyranoside 
formation.   
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Figure 1.1: Acid catalyzed DPM etherification with trichloroacetimidate 1.1 
 
 Schmidt and Michel have demonstrated a use for trichloroacetimidates in glycosidic bond 
formation.10  Facile conversion of the glucopyranose to the corresponding imidate is done with 
base and trichloroacetonitrile or aryl-substituted ketenimines.  Then the isolated imidate can be 
used for an acid catalyzed reaction with another glucopyranose to form a glycosidic bond (Figure 
1.2).  This methodology avoids using heavy metal salts such silver salts which were previously 
utilized for glycoside synthesis.       
Figure 1.2: Glycosidic bond formation with trichloroacetimidate 
 
 Trifluoroacetimidates have also been utilized in the benzylation of alcohols.11,12  These 
imidates can be prepared from a one pot reaction of benzyl alcohols via perfluoro nitriles from an 
amide dehydration.  Perfluoro nitriles can be difficult to use since they are extremely volatile and 
toxic.  In a related study, Pohl investigated a number of N-aryl trifluoroacetimidates for the 
installation of benzyl and allyl protecting groups on carbohydrates (Figure 1.3).  These 
trifluoroacetimidates are prepared from N-aryl trifluoroacetimidoyl chlorides, benzyl or allyl 
alcohol and base.  Employing an electron withdrawing phenyl group on the nitrogen of the 
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imidate allows for a more stable imidate but still provides reactivity as a leaving group.  The 
perfluoroacetimidates are stable at room temperature for several days.  These imidates have been 
reported to alkylate alcohols in one hour at room temperature.  However, the alkylation employs 
the use of an acid catalyst such as TfOH or TMSOTf.  
Figure 1.3: Alkylation with Trifluoroacetimidate 
 
Kunishima also established a method for preparing benzyl ethers at room temperature 
with triazinylammonium salts (Figure 1.4).  4-(4,6-Diphenoxy-1,3,5-triazin-2-yl)-4-
benzylmorpholinium trifluoromethanesulfonate (DPT-BM) is prepared from 4,6-diphenoxy-2-
trifluoromethanesulfonyloxy-1,3,5-triazine and 4-benzylmorpholine.13  This triazinylammonium 
salt is a non-hygroscopic, stable solid and can be stored at cold temperatures for long periods of 
time.  This reagent was used to benzylate primary, secondary and tertiary alcohols in high yields.  
This alkylation also performed well on acid and base sensitive substrates such as acetoxy, β-
hydroxyester, and silyl groups.  The major caveat with this reaction is that it uses MgO as an acid 
scavenger and dehydrating reagent, which introduces another variable into the reaction and could 
lead to degradation of sensitive molecules.  Kunishima has also reported alkylation of alcohols 
with benzyl or p-methoxybenzyl groups using 2,4,6-tris(benzyloxy)-1,3,5-triazine (TriBOT) and 
2,4,6-tris(p-methoxybenzyloxy)-1,3,5-triazine (TriBOT-PM), respectively.14, 15  However, this 
method also uses catalytic acid to make the corresponding ethers.   
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Figure 1.4: Ether Formation with Triazinylammonium salts: 
 
 Phosphinimidates have also been explored for their use in the alkylation of alcohols 
(Figure 1.5) under mild conditions.16  These stable imidates are made from alkyl 
diphenylphosphinites and methanesulfonyl azide.  The ether formation worked well when a 
strong electron withdrawing group was bonded to the nitrogen of the phosphinimidate.  The 
alkylation was also quite general, and performed well on primary, secondary and tertiary 
alcohols as well as carbohydrates.  One drawback to using phosphinimidates as alkylating agents 
is that they need catalytic amount of TMSOTf for the transformations to occur.   
Figure 1.5:  Alkylation with Phosphinimidates          
 
 Dudley has reported the protection of alcohols as benzyl and p-methoxybenzyl groups 
using 2-benzyloxy-1-methylpyridinium triflate (Bn-OPT) and 2-(4-methoxybenzyloxy)-4-
methylquinoline, respectively, in refluxing α,α,α-trifluorotoluene (Figure 1.6).17  Bn-OPT is a 
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novel benzylation reagent for alcohols, stable solid, and preactivated.  It is prepared by treating 
2-benzyloxypyridine with methyl triflate and can be made in situ in the presence of alcohol.  The 
benzylation works well with primary, secondary, and tertiary alcohols.  This etherification also 
worked with β-hydroxyesters and trimethylsilylethanol.  However, reaction with cinnamyl 
alcohol only provided trace amounts of product.  Additionally in order to prepare this reagent, 
the toxic and carcinogenic methyl triflate must be prepared and used. Alkylation with 2-(4-
methoxybenzyloxy)-4-methylquinoline also worked on primary, secondary, and tertiary alcohols.  
This method created by Dudley use additives such as MgO which is a mild base and desiccant to 
scavenge acid or water.  Therefore, this etherification could prove difficult with base sensitive 
functionality.     
Figure 1.6: Etherification with Pyridinium Salts 
 
 While many reagents have been created to address the problem of protecting alcohols 
under mild conditions in sensitive systems, work towards a general, inexpensive and nontoxic 
solution which does not require a strong acid catalyst is still ongoing. In the next chapter we will 
discuss investigations into utilizing trichloroacetimidates for these transformations without the 
addition of an acid promoter, providing an alternative solution for the formation of some esters 
and ethers under mild conditions. 
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Chapter 2: Formation of Esters, Thioethers and Ethers with Trichloroacetimidate 
Electrophiles under Catalyst-Free Conditions 
Abstract: 
 Many reagents have been developed to form benzyl ethers and esters under mild, neutral 
conditions that and do not disturb the sensitive functionality in complex molecules.  Most of 
these reagents are based on acetimidate-type systems, as the rearrangement of these systems to 
the corresponding acetamide provides a secondary thermodynamic driving force for the ether 
formation. Trichloroacetimidates are effective at alkylating carboxylic acids, thiols, and alcohols 
under Lewis acid catalyzed conditions, but little attention has been given to their reactivity under 
catalyst free conditions.  Given their ready availability, a reevaluation of the reactivity of 
alcohols and trichloroacetimidates has been undertaken.  In many cases, simply heating the 
trichloroacetimidate with an alcohol in refluxing toluene without an exogenous acid or base is an 
effective method for the formation of the desired ether. This operationally simple procedure is 
most effective for trichloroacetimidates that are precursors to highly stabilized cations (i.e. the 4-
methoxybenzyl and diphenylmethyl group).  Esters, thioethers and ethers were formed without 
the use of an acid or base catalyst. Thermal etherification was performed under neutral 
conditions with both the DPM and PMB trichloroacetimidate. The use of this new procedure 
with a number of acid and base sensitive substrates, which are protected in excellent yield 
without disturbing the delicate functionality present in these molecules, is presented.  
1. Catalyst-Free Protection of Esters with Trichloroacetimidates  
Carboxylic acids are often protected as esters in multistep organic synthesis.  Popular ester 
protecting groups for carboxylic acids include the 4-methoxybenzyl (PMB) and diphenylmethyl 
(DPM) esters.1,2  These protecting groups are often used due to their ease of removal via treatment 
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with acid or by hydrogenation (they may also be removed by saponification).1-7  Carboxylic acids 
are typically protected with a PMB group through alkylation reactions with the corresponding 
halide and a strong base.  DPM esters can be installed with acid catalysis using diphenylmethanol 
as the electrophile or by treating the carboxylic acid with diphenyldiazomethane.8,9,10  The problem 
with most of these protecting group installations is that they do not tolerate complex substrates 
with sensitive functionality or they incorporate environmentally hazardous reagents.9  
Trichloroacetimidates have been used for ester formation through their reaction with carboxylic 
acids in the presence of an acid catalyst.11  There have been scattered reports of ester formation 
with trichloroacetimidates without the addition of a catalyst, however. For example, Hayashi and 
co-workers have reported the formation of a PMB ester without a catalyst using 4-methoxybenzyl-
2,2,2-trichloroacetimidate directly.3,4  Two other examples of catalyst free esterification are also 
present in the literature, with glycosyl imidates and 2-phenylisopropyl trichloroacetimidate 
undergoing these reactions.12,13  In the examples where a catalyst is not needed for esterification, 
the imidate may be protonated by the carboxylic acid and then ionize to form a carbocation, which 
is then trapped by the carboxylate anion. All of these examples of ester formation with 
trichloroacetimidates use imidates that are precursors to stable carbocations.  Loss of the imidate 
and formation of trichloroacetamide thermodynamically facilitates the alkylation reaction.  Given 
that little was known about the scope of these reactions, an investigation using PMB and DPM 
trichloroacetimidates to form their respective esters of carboxylic acids without an acid catalyst 
was initiated.   
The formation of esters from trichloroacetimidates may occur by either an SN1 or an SN2 
mechanism (Figure 2.1 shows the possible mechanisms for the reaction of a carboxylic acid with 
PMB trichloroacetimidate 2.1).  For SN1 addition, the carboxylic acid substrate promotes the 
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reaction by protonating the basic imidate nitrogen.  After acetamide 2.3 is formed, the carboxylate 
anion can add to the PMB cation. In SN2 addition, the carboxylic acid adds to the benzylic position 
of the PMB imidate causing the acetamide anion to form.  The acetamide anion then removes the 
hydrogen from the protonated acid, forming the PMB ester.  A concerted SN2 mechanism involving 
a 6-membered transition state between the carboxylic acid and the PMB imidate is also a 
possibility.   
Figure 2.1: Proposed Mechanisms of PMB esterification 
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 Ester formation without the presence of an acid catalyst using PMB imidate 2.1 was 
initially explored.  PMB imidate 2.1 is commercially available and may also be easily prepared 
from PMB alcohol and trichloroacetonitrile using DBU or NaH as a catalyst.14 Several carboxylic 
acids were successfully treated with PMB imidate 2.1 to form their corresponding esters without 
an added acid catalyst (Table 2.1).15  This simple reaction is carried out at room temperature in 
dichloromethane.  Diverse substrates tolerated the esterification such as alkanes, alkenes, alkynes, 
and electron rich and electron poor benzoic acids.  Under these conditions, carboxylic acids are 
selectively protected over other functional groups such as alcohols.  
Table 2.1: Esterification with PMB Imidate 
 
Entry Compound % Yield 
1 
 
43% 
2 
 
60% 
3 
 
54% 
4 
 
64% 
13 
 
5 
 
50% 
6 
 
63% 
7 
 
80% 
8 
 
51% 
9 
 
27% 
10 
 
25% 
  
 Ester formation was successful for the compounds in Table 2.1, resulting in moderate to 
high yields.  Esterification of acetylsalicylic acid gave the highest yield of 80%.  The isobutyl 
ester in entry 1 provided a low yield most likely due to steric effects from the isobutyl group on 
the acid.  Entries 2 and 7 demonstrate that ortho substituents are tolerated on benzoic acid 
derivatives for this methodology, so some tolerance of sterically demanding substrates was 
demonstrated.  No isomerization was observed for the alkene in entry 3.  Entries 4, 5 and 6 
provided moderate yields most likely due to sterics from the bulky R groups next to the 
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carboxylic acids.  The highly strained cyclopropyl carboxylic acid provided the respective PMB 
ester in 51 % yield (entry 8), but no opening of the cyclopropane was observed.  Entries 9 and 10 
again gave lower yields due to sterics of the corresponding carboxylic acids.  This study provides 
evidence that PMB esters can be formed under mild reaction conditions using the 
trichloroacetimidate, and provides a mild method which may be useful for forming PMB esters 
in complex multifunctional substrates.15 Sterically hindered carboxylic acids may provide lower 
yields due to sterics, however. 
Building on the success with PMB trichloroacetimidate, diphenyl methyl 
trichloroacetimidate was evaluated as an esterification reagent under catalyst-free conditions 
(Figure 2.2).  Diphenylmethyl trichloroacetimidate was postulated to be an effective alkylating 
agent because it can lead to a  stabilized carbocation, facilitating the SN1 substitution pathway 
with a carboxylic acid.  Also, it is a easy to handle white solid that is stable in cold storage for 
long periods of time and can be easily prepared from the inexpensive diphenylmethanol in high 
yield.16  Ester formation was successful for both tert-butylacetic acid 2.15 and adamantane-1-
carboxylic acid 2.18 with DPM imidate 2.16 under neutral conditions.  Esterification of tert-
butylacetic acid gave a high yield of 92% while adamantane-1-carboxylic acid was not as 
reactive which is most likely because of sterics.  This study provides evidence that DPM esters 
such as 2.17 and 2.19 may also be formed under mild reaction conditions using the 
trichloroacetimidates.17 
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Figure 2.2: Esterification with DPM Imidate 
 
 
2. Thioethers 
Building on the esterification work, the alkylation of thiols was then attempted under 
catalyst-free conditions. Thiols are less acidic than alcohols, but more acidic than alcohols, so 
their alkylation was explored next.  Sulfides are commonly present in molecules used for 
pharmaceuticals, enzyme cofactors, and pesticides.18,19,20  Sulfides are often synthesized from the 
alkylation of thiols with alkyl halides or alcohols.21  However, these classic methods employ the 
use of an acid or base catalyst, which may provide problems in complex molecules.22   
Trichloroacetimidates were effective in the alkylation of thiols to form thioethers without 
the addition of an acid, base or metal catalyst (Figure 2.3). This new method for sulfide 
formation involves simply refluxing the thiol and imidate in THF.  Both alkyl and aromatic thiols 
can be used with this method. Also, a variety of trichloroacetimidates including alkyl, allylic, 
propargylic and benzylic imidates performed well in the alkylation reaction.23   
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Figure 2.3: Sulfide formation with imidates 
 
 
Figure 2.4 shows two mechanistic possibilities for this thiol alkylation.  Depending on the 
electrophile, this reaction can proceed through either a SN1 or SN2 pathway.  The first step for 
both mechanisms is the imidate gets protonated by the thiol, creating a thiolate anion.  Should the 
electrophile be suitable for SN2 conditions, the sulfur anion will attack with the R
’ group from the 
protonated imidate and the acetamide 2.3 is formed directly.  A concerted SN2 process as shown 
in Figure 2.1 may also be possible with a thiol. For the SN1 pathway, the protonated imidate 
forms the acetamide and an R’ cation.  Then the thiolate will then attack the R’ cation to give the 
thioether.   
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Figure 2.4 Mechanistic possibilities for thioether formation with trichloroacetimidates 
 
Thiol displacement of methyl trichloroacetimidate under these conditions to form a 
methyl thioether supported the SN2 mechanism. Furthermore, thiol reaction with chiral imidate 
supports an SN2 mechanism (Figure 2.5).  The reaction proceeded with inversion forming sulfide 
2.28, with none of the retention product being observed by 1H NMR (the retention product was 
independently synthesized for comparison).  
Figure 2.5: Thiol reaction with chiral imidate 
 
 
3. Ethers 
 After formation of sulfides with trichloroacetimidates under catalyst free conditions, 
attention was turned to the etherification of alcohols. Trichloroacetimidates have been routinely 
used to protect alcohols as ethers at room temperature in the presence of a Brønsted or Lewis 
acid catalyst.24-29  Schmidt and co-workers have employed diphenylmethyl trichloroacetimidate 
2.16 to make diphenylmethyl (DPM) ethers with a catalytic amount of TMSOTf in excellent 
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yields.16  The use of an acid catalyst for this reaction limits the substrates which can participate 
in the etherification.  An example of a problematic acid sensitive substrate would be β-
trimethylsilylethanol, which has been reported to be subjected to a Peterson elimination under 
acidic conditions with a trichloroacetimidate.30  Other reagents similar to trichloroacetimidates 
have also been developed for the synthesis of benzyl and PMB ethers.31,32  Additionally, 
trifluoroacetimidate and phosphinimidate type reagents have been introduced for etherification, 
however these systems still require the use of an acid cataylst.33,34   
 Diphenylmethyl (DPM) ethers are frequently used as protecting groups for alcohols in 
organic synthesis.35  They can easily be removed through hydrogenation or with acidic 
conditions making the DPM group useful in complex molecules where more than one protecting 
group is in place.36,24  DPM ethers have also proven beneficial for enantioselective reactions 
since the steric bulk of the group can show increased selectivity in some substrates.37  The DPM 
group is also commonly used in medicinal chemistry since the phenyl rings add large 
hydrophobic groups which increase the lipophilicity of biologically active molecules.38 
Trichloroacetimidates have been utilized in the Chisholm laboratory to explore ester and 
sulfide formation.15,17,23  Given the high reactivity of the PMB and DPM trichloroacetimidates 
with carboxylic acids and thiols, these substrates were chosen for initial exploration as 
etherification reagents under catalyst-free conditions. PMB and DPM ethers are also commonly 
used protecting groups, so these methods should have some utility in the synthetic organic 
community.  Studies with DPM imidate 2.16 have shown that the rearrangement of the imidate 
to the corresponding acetamide occurs when the imidate is refluxed in toluene.  This type of 
rearrangement is similar to reports of benzylic imidates undergoing rearrangement through a 
cationic pathway in the presence of a strong acid.39  We hypothesized that under thermal 
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conditions a similar process occurs and the DPM imidate ionizes to form a DPM cation and 
trichloroacetamide anion.  The cation could be intercepted by an external nucleophile such as an 
alcohol.  This hypothesis would allow for the formation of DPM ethers under thermal conditions 
without the use of an acid or base additive.  Conditions have now been developed for ether 
formation under neutral conditions without a catalyst, which typically proceed in moderate to 
high yields with DPM and PMB imidates.40       
Diphenylmethyl (DPM) imidate was synthesized from benzophenone (Figure 2.6).  
Reduction of benzophenone to diphenylmethanol is easily done with sodium borohydride in 
methanol.  The treatment of the diphenylmethanol with trichloroacetonitrile (TCAN) in the 
presence of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) provided DPM imidate 2.16.  Alfa-Aesar 
quotes diphenylmethanol at $25.97/mol, TCAN at $36.94/mol and $38.06/mol, allowing for a 
very cost effective synthesis of DPM imidate.  The DPM imidate 2.16 showed stability for long 
periods of time when stored cold in a refrigerator and is very easy to handle since its physical 
form is a white powder.  
Figure 2.6: Synthesis of DPM Imidate 
 
 Earlier studies with DPM imidate 2.16 demonstrated that the imidate would rearrange to 
the corresponding trichloroacetamide when refluxed in toluene (Figure 2.7).  Rearrangements of 
allylic trichloroacetimidates are known and usually occur through a concerted [3,3]-sigmatropic 
rearrangement (the Overman rearrangement, Figure 2.8).41  However, this rearrangement is less 
favorable for the DPM imidate.  Instead, the rearrangement is believed to occur through a 
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cationic pathway, where the imidate ionizes under thermal conditions due to the stability of the 
diphenylmethyl cation.  This allows cation 2.32 and trichloroacetamide anion 2.31 to form. The 
trichloroacetamide anion is a weak base and poor nucleophile with a pKa of approximately 11.41  
An added external nucleophile, such as an alcohol, may therefore intercept the cation 2.32 and 
form the corresponding DPM ether. 
Figure 2.7: Intercepting the DPM cation  
 
Figure 2.8: The Overman rearrangement 
 
Our thermal etherification studies began with an exploration of reaction conditions.  A 
solvent screen with 1-octadecanol 2.34 and DPM imidate 2.16 showed that performing the 
reaction in toluene at reflux gave the best isolated yield of the corresponding DPM ether product 
(Table 2.2, entry 1). Lower temperatures in toluene provided a lower yield of the desired ether 
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product (entry 2), which was attributed to a slower reaction.  Nonpolar solvents appeared to be 
superior for the etherification reaction, with acetonitrile and DMF providing the lowest yields 
(entries 8 and 9 respectively). 
Table 2.2:  Solvent Screen of Etherification with DPM Imidate  
 
Entry Solvent Temperature (oC) % Yield 
1 Toluene 111 85 
2 Toluene 50 24 
3 Trifluorotoluene 102 62 
4 1,2-Dichloroethane 83 66 
5 Dichloromethane 40 18 
6 Tetrahydrofuran 66 36 
7 1,4-Dioxane 101 60 
8 Acetonitrile 82 28 
9 Dimethylformamide 110 33 
 
This catalyst-free etherification was then evaluated with a variety of alcohols to 
determine the scope of the reaction (Table 2.3).  The reaction provided very high yields with 
benzyl alcohols in entries 1, 2, 3, and 4.  Entries 5, 6, 7, 8 show allylic alcohols and phenol 
derivatives also participate in this reaction.  Propargyl alcohol (entry 12) also proved to be an 
excellent reactant in the transformation, providing a 97% yield of propargyl ether product.  The 
etherification of secondary and tertiary alcohols (entries 9, 10, 11) also proceeded in high yields.  
This is notable, as many other catalyst-free etherification conditions do not provide high yields 
with tertiary alcohols.30  Entries 13, 14, and 15 demonstrate that more complex alcohols can be 
protected with this methodology.  Acid and base sensitive alcohols may also be protected with 
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this procedure as shown in entries 16-18.  The protection of 2-trimethylsilyl ethanol to form ether 
2.53 is particularly notable, as this substrate decomposes under acidic and basic conditions,30 yet 
is effectively protected under the new thermal conditions. Diols may also be mono protected 
with this methodology (entries 21-24), although the yields are moderate.  In the case of mono 
protection only one equivalent of DPM imidate was used for the ether formation.  Small amounts 
of diprotected ether were observed for the symmetrical diols.  Entries 23 and 24 gave low yields 
because of the difficult separation of the mixture of mono protected alcohols.  These reactions 
demonstrate that DPM ethers can be formed with neutral conditions using trichloroacetimidates. 
The ability to monoprotect alcohols preferentially may be explained by the greater acidity of the 
diol when the two alcohols form an intramolecular hydrogen bond, this was further explored 
with PMB trichloroacetimidate and is discussed later in this chapter. 
Table 2.3:  Etherification with DPM Imidate  
 
Entry Alcohol % Yield 
1 
 
94% 
2 
 
71% 
3 
 
92% 
4 
 
88% 
23 
 
5 
 
91% 
6 
 
61% 
7 
 
53% 
8 
 
88% 
9 
 
93 % 
10 
 
85% 
11 
 
92% 
12 
 
97% 
13 
 
80% 
14 
 
80% 
15 
 
96% 
16 
 
65% 
17 
 
73% 
18 
 
79% 
24 
 
19 
 
90% 
20 
 
91% 
21 
 
68% 
22 
 
40% 
23 
 
38% 
24 
 
19% 
 
 No racemization was observed in the formation of chiral ethers 2.54 and 2.55 through 
chiral HPLC analysis (Figure 2.8).  Chiral and racemic serine protected ethers were prepared for 
comparison on chiral HPLC.  The chiral HPLC traces show that no racemization occurs under 
the thermal etherification conditions.  The same was observed for chiral ethyl lactate 2.54 
(Figure 2.9).     
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Figure 2.9: Chiral DPM ethers 
 
 
 
Since ether formation from alcohols performed well with DPM imidate, a study was 
initiated with 4-methoxybenzyl (PMB) imidate.  Both the PMB and DPM imidates have been 
shown to react with carboxylic acids to form esters without the need for an acid catalyst, so the 
PMB ether may also be reactive enough to form ethers under thermal conditions. PMB ethers are 
more common protecting groups for alcohols and can be easily removed under mild oxidation 
conditions.1,2  Since the PMB imidate is an oil, PMB protection under solvent free conditions 
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was initially explored (Figure 2.10).  These neat reactions were performed with either 1-
octadecanol or cinnamyl alcohol and 3 equivalents of PMB imidate at 110 oC overnight.  This 
resulted in a good yield for 1-octadecanol, but only a 17% yield of the cinnamyl ether was 
obtained under these conditions. The addition of 10 mol% trichloroacetamide was also explored 
to see if the acetamide was catalyzing the reaction.  The yield improved slightly for cinnamyl 
alcohol with the addition of trichloroacetamide but had little effect in the case with 1-
octadecanol.  As these conditions were not general and yields were moderate, a solvent screen 
was performed for the PMB etherifications (Table 2.4).   
Figure 2.10: Neat PMB Ether Reactions 
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Table 2.4: PMB Ether Solvent Screen 
 
Entry  Solvent Temperature (oC) % Yield 
1 Toluene 111 70 
2 Toluene 80 27 
3 Toluene 50 23 
4 Trifluorotoluene 102 73 
5 1,2-Dichloroethane 83 74 
6 Dichloromethane 40 17 
7 Dichloromethane r.t. 4 
8 Tetrahydrofuran 66 40 
9 1,4-Dioxane 101 25 
10 Acetonitrile 82 18 
11 Dimethylformamide 110 11 
 *0.25 M concentration 
 The solvent screen showed dichloroethane at reflux giving the best yield of PMB ether 
2.60.  -Trifluorotoluene and toluene gave good yields when used at reflux.  More polar 
solvents did not give good yields, as the imidate decomposed rapidly under these conditions. 
Less polar solvents at lower temperatures typically returned starting material, leading to the 
conclusion that a temperature in excess of 80 °C was required for the etherification. Alcohol 
protection with PMB imidate was therefore initially explored in DCE at reflux.  However, PMB 
protection with DCE gave low yields on most substrates.  Toluene was then tested as the solvent 
in hopes that heating the reaction to a higher temperature would improve reaction yields. Figure 
2.11 shows PMB etherification of 1-octadecanol (2.34) at concentrations of 0.25 M, 0.5 M, and 
1.0 M.  Both reactions at concentrations of 0.5 M and 1.0 M gave high yields. PMB 
etherifications were then performed in toluene at 1.0 M. 
28 
 
 Figure 2.11:  Concentration Studies 
 
Cinnamyl alcohol is an interesting substrate because it is an allylic alcohol.  Protection of 
allylic alcohols have been previously reported in low yields with some PMB etherification 
reagents,42 so they were chosen as a test of the methodology.  Figure 2.12 shows a study of the 
PMB etherification of cinnamyl alcohol under various conditions.  The etherifications were 
carried out at 1 M concentration and went for 24 hours unless otherwise noted.  PMB protection 
of cinnamyl alcohol in toluene only yielded 28% of the ether product.  One possibility for the 
low yield is that adventitious water was hydrolyzing the imidate, which led to the low yield.  
Therefore, a series of drying reagents were tested in the PMB etherification.  Molecular sieves, 
barium oxide and magnesium oxide all led to decreased yield for the etherification.  
Trichloroacetamide was also tested as a possible catalyst for the etherification but these 
conditions gave comparable yield of PMB protected cinnamyl alcohol as observed with the neat 
conditions.  
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Figure 2.12: PMB Etherification with Cinnamyl Alcohol 
 
 Since PMB protection of cinnamyl alcohol in toluene with various additives gave poor 
results, a new solvent was tested.  Toluene may be destroying the imidate through a Friedel-
Crafts process (although these products were never observed directly by 1H NMR), so a more 
electron deficient solvent that was less likely to undergo Friedel-Crafts alkylation was utilized.  
Therefore, α,α,α-trifluorotoluene was explored as the solvent (Figure 2.13).  The etherification in 
α,α,α-trifluorotoluene gave a 52% yield of the PMB protected cinnamyl alcohol.  The 
etherification was allowed to proceed for two days in hopes of a higher product yield but the 
yield decreased to 32%. This may mean that shorter reaction times should be explored as a 
means to increase the reaction yield, but first a number of other alcohol substrates were evaluated 
at the 24 h time point (Table 2.5). 
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Figure 2.13: PMB Etherification with Cinnamyl Alcohol in α,α,α-Trifluorotoluene 
 
 Since α,α,α-trifluorotoluene provided the PMB protected cinnamyl alcohol in moderate 
yield, α,α,α-trifluorotoluene was chosen as the solvent for substrate testing.  The results of PMB 
etherification in α,α,α-trifluorotoluene are shown in Table 2.5.  Entries 1-4 demonstrate that the 
methodology performs well with electron rich and electron poor benzyl alcohols.  Propargyl 
alcohol gave an 85% yield of its PMB ether; however, the tertiary propargyl alcohol yielded no 
reaction product (entries 5-6).  Other tertiary alcohols, like adamantyl alcohol, did provide some 
product although the yields were more moderate than observed for the DPM imidate.  Entry 8 
demonstrates PMB etherification of an electron poor phenol works with a 76% yield.  The 
dihydrocholesterol derivative, a secondary alcohol, in entry 11 provided a 55% yield, which 
again is lower than was observed for secondary alcohols in the case of the DPM imidate.  Entries 
9-10 and 12-16 are more complex examples that are acid and base sensitive.  These examples 
gave moderate to low yields demonstrating the PMB imidate is significantly less reactive than 
the DPM imidate.  Further studies on the reaction conditions or the use of a more reactive 
imidate (like 2,4-dimethoxybenzyl or 2,6-dimethoxybenzyl) may be required to access a more 
general system for the benzyl protection of alcohols. 
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Table 2.5: PMB Etherifications in α,α,α-Trifluorotoluene  
 
Entry Product % Yield 
1 
 
81% 
2 
 
78% 
3 
 
85% 
4 
 
67% 
5 
 
85% 
6 
 
NR 
7 
 
40% 
8 
 
76% 
9 
 
33% 
32 
 
10 
 
15% 
11 
 
55% 
12  68% 
13 
 
58% 
14 
 
25% 
15 
 
61% 
16 
 
23% 
PMB etherification was also performed on a number of diols (Table 2.6).  The lower 
reactivity of the PMB imidate may be beneficial in these cases, as higher selectivity may be 
accessed for these systems. Entry 1 shows the mono PMB protected 1,4-butanediol in 59 % 
yield.  This yield is expected since in the presence of one equivalent of imidate a 2:1:1 mixture 
of mono product: dialkylated product: starting material is predicted.  Entry 2 is the dialkylated 
product of 1,4-butanediol and was obtained in only a 41% yield.  Primary alcohols can 
selectively be protected in the presence of secondary and tertiary alcohols (entries 3, 4).  Some 
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diols undergo monoprotection in much higher yields than could be anticipated a priori, for 
example entries 5 and 6 were obtained in 80% and 79% yield respectively.   
Table 2.6: PMB Etherification of Diols 
 
Entry Product % Yield 
1 
 
59%a 
2 
 
41%b 
3 
 
34%a 
4 
 
68%a 
5 
 
80%a 
6 
 
79%a 
7 
 
36%a 
   a 1 eq. of PMB imidate was used. 
   b 3.3 eq. of PMB imidate were used. 
 
 The yield of the monoprotected product in these reactions is significantly higher than one 
would predict based on statistical reactivity of the diols. The ability of these systems to form 5 
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and 6 membered hydrogen bonds (Figure 2.14) may explain this reactivity.  One of the 
hydrogens becomes more acidic when the diol is participating in this hydrogen bonding, leading 
to the selective formation of the monoprotected ether.  This intramolecular H-bonding is not 
possible after monoprotection.  The alkyne in entry 7 restricts that capability for hydrogen 
bonding and therefore gave a lower yield of the monoprotected product (36%), further 
supporting the role of hydrogen bonding in these systems.   
 
Figure 2.14: Hydrogen bonding in diols 
 
A one-pot PMB etherification from 4-methoxybenzyl alcohol was also attempted (Figure 
2.15).  In this procedure, the PMB imidate is generated in situ and not isolated.  After the PMB 
imidate is observed by TLC, 4-nitrobenzyl alcohol was added.  This alcohol was chosen because 
of its high reactivity in the PMB etherification.  These experiments were performed in both 
toluene and α,α,α-trifluorotoluene.  The reaction in toluene only gave 15% yield of PMB 
protected product while the reaction in α,α,α-trifluorotoluene gave 34% yield of product. These 
poor yields may be due to the imidate forming in low yield in these solvents, as typically the 
imidate formation is performed in diethyl ether. 
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 Figure 2.15: One Pot PMB Etherification 
  
 
Conclusions and Future Work 
 Thermal etherification was successful with both DPM and PMB imidate.  Neutral, 
thermal conditions do not require an acid or base catalyst for etherification. The DPM imidate 
was found to be more reactive under these conditions, and therefore the method was more 
general with regard to the alcohol substrates. This novel methodology allows for alcohol 
protection on sensitive substrates.  Chirality centers are also undisturbed when subjected to the 
reaction conditions.  Trichloroacetimidates were used to alkylate carboxylic acids and thiols as 
well.  Etherification using trichloroacetimidates under mild conditions will continue to be 
explored.  Further investigation using different substrates will be conducted.   Etherification of 
alcohols with other imidates will also be studied using similar, neutral conditions.  Imidates with 
more electron rich groups, such as 2,4- or 2,6-dimethoxybenzylimidate, will be tested to see if 
reaction conditions and yields improve as compared to the 4-methoxybenzyl 
trichloroacetimidate. 
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Experimental Procedures 
General Information. All anhydrous reactions were run under a positive pressure of argon or 
nitrogen. All syringes, needles, and reaction flasks required for anhydrous reactions were dried in 
an oven and cooled under an N2 atmosphere or in a desiccator. DCM and THF were dried by 
passage through an alumina column by the method of Grubbs.1 Triethylamine was distilled from 
CaH2. All other reagents and solvents were purchased from commercial sources and used without 
further purification. 
Analysis and Purification. Analytical thin layer chromatography (TLC) was performed on 
precoated glass backed plates (silica gel 60 F254; 0.25 mm thickness). The TLC plates were 
visualized by UV illumination and by staining. Solvents for chromatography are listed as 
volume:volume ratios. Flash column chromatography was carried out on silica gel (40-63 μm). 
Melting points were recorded using an electrothermal melting point apparatus and are uncorrected. 
Elemental analyses were performed on an elemental analyzer with a thermal conductivity detector 
and 2 meter GC column maintained at 50 °C. 
Identity. Proton (1H NMR) and carbon (13C NMR) nuclear magnetic resonance spectra were 
recorded at 300 or 400 MHz and 75 or 100 MHz respectively. The chemical shifts are given in 
parts per million (ppm) on the delta (δ) scale. Coupling constants are reported in hertz (Hz). The 
spectra were recorded in solutions of deuterated chloroform (CDCl3), with residual chloroform ( 
7.26 ppm for 1H NMR, δ 77.23 ppm for 13C NMR) or tetramethylsilane ( 0.00 for 1H NMR,  
0.00 for 13C NMR) as the internal reference. Data are reported as follows: (s = singlet; d = doublet; 
t = triplet; q = quartet; p = pentet; sep = septet; dd = doublet of doublets; dt = doublet of triplets; 
td = triplet of doublets; tt = triplet of triplets; qd = quartet of doublets; ddd = doublet of doublet of 
doublets; br s = broad singlet). Where applicable, the number of protons attached to the 
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corresponding carbon atom was determined by DEPT 135 NMR. Infrared (IR) spectra were 
obtained as thin films on NaCl plates by dissolving the compound in CH2Cl2 followed by 
evaporation or as KBr pellets. 
 
 
4-methoxybenzyl 3,3-dimethylbutanoate 2.5  
In a flame dried 50 mL round bottom flask, tert-butylacetic acid (400 mg, 3.44 mmol) was 
dissolved in dry dichloromethane (14 mL).  4-methoxybenzyl 2,2,2-trichloroacetimidate (1.934 
g, 3.44 mmol) was added.  The reaction was stirred at room temperature for 24 hours.  The 
reaction was taken up in ethyl acetate, washed with sat. aq. sodium bicarbonate three times, dried 
with sodium sulfate and concentrated.  Purification was done with flash column chromatography 
(10% ether/hexane) to give a clear oil (346 mg, 43%). TLC Rf = 0.58 (15% ethyl 
acetate/hexanes); IR (neat) 2957, 2836, 1731, 1515 cm-1; 1H NMR (300 MHz, CDCl3): δ 7.30 (d, 
J = 9.0 Hz, 2H), 6.89 (d, J = 8.6, 2H), 5.04 (s, 2H), 3.81 (s, 3H), 2.22 (s, 2H), 1.01 (s, 9H);  13C 
NMR (75 MHz, CDCl3):  δ 172.3, 159.7, 130.2, 128.5, 114.0, 65.8, 55.3, 48.1, 30.9, 29.8.  Anal 
calcd for C14H20O3: C, 71.16; H, 8.53.  Found: C, 71.37; H, 8.37.      
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4-methoxybenzyl 2-methoxybenzoate 2.6 
 In a flame dried 50 mL round bottom flask, o-anisic acid (400 mg, 2.63 mmol) was dissolved in 
dry dichloromethane (11 mL).  4-methoxybenzyl 2,2,2-trichloroacetimidate (1.486 g, 5.26 mmol) 
was added.  The reaction was stirred at room temperature for 24 hours.  The reaction was taken 
up in ethyl acetate, washed with sat. aq. sodium bicarbonate three times, dried with sodium 
sulfate and concentrated.  Purification was done with flash column chromatography (10% ethyl 
acetate/hexanes) to give a clear oil (433 mg, 60%).  TLC Rf = 0.56 (25% ethyl acetate/hexanes); 
IR (neat) 2956, 2837, 1724, 1514, 1245 cm-1;  1H NMR (300 MHz, CDCl3) δ 7.81 (d, J = 9.8 Hz, 
1H), 7.37-7.47 (m, 3H), 6.89-6.97 (m, 4H), 5.29 (s, 2H), 3.88 (s, 3H), 3.79 (s, 3H);  13C NMR 
(75 MHz, CDCl3) δ 166.0, 159.6, 159.4, 133.6, 131.7, 130.0, 128.4, 120.1, 113.9, 112.1, 66.4, 
56.0, 55.3. 
 
 
(E)-4-methoxybenzyl but-2-enoate 2.7  
Lit. Ref.:  Matsuo, J.; Kozai, T.; Ishibashi, H. Org. Lett. 2006, 8 (26), pp 6095–6098. 
In a flame dried 50 mL round bottom flask, crotonic acid (400 mg, 4.65 mmol) was dissolved in 
dry dichloromethane (19 mL).  4-methoxybenzyl 2,2,2-trichloroacetimidate (1.972 g, 6.98 mmol) 
was added.  The reaction was stirred at room temperature for 24 hours.  The reaction was taken 
up in ethyl acetate, washed with sat. aq. sodium bicarbonate three times, dried with sodium 
sulfate and concentrated.  Purification was done with flash column chromatography (10% ethyl 
acetate/hexanes) to give a clear oil (515 mg, 54%).  TLC Rf = 0.25 (15% ethyl acetate/hexanes); 
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IR (neat) 3001, 2955, 2837, 1716, 1613, 1515, 1249 cm-1;  1H NMR (300 MHz, CDCl3) δ 7.31 
(d, J = 8.7 Hz, 2H), 6.93-7.06 (m, 1H), 6.89 (d, J = 8.7 Hz, 2H), 5.87 (d, J = 15.0 Hz, 1H), 5.10 
(s, 2H), 3.80 (s, 3H), 1.86 (d, J = 6.0 Hz, 3H);  13C NMR (75 MHz, CDCl3) δ 166.4, 159.7, 
145.0, 130.1, 128.4, 122.7, 114.0, 65.8, 55.3, 18.0. 
 
4-methoxybenzyl-1-adamantanoate 2.8 
Lit. Ref.: Rolfe, A.; Loh, J. K.; Maity, P. K.; Hanson, P. R. Org. Lett. 2011, 13, 4-7. 
In a flame dried 50 mL round bottom flask, 1-adamantanecarboxylic acid (400 mg, 2.22 mmol) 
was dissolved in dry dichloromethane (9 mL).  4-methoxybenzyl 2,2,2-trichloroacetimidate 
(1.255 g, 4.44 mmol) was added.  The reaction was stirred at room temperature for 24 hours.  
The reaction was taken up in ethyl acetate, washed with sat. aq. sodium bicarbonate three times, 
dried with sodium sulfate and concentrated.  Purification was done with flash column 
chromatography (10% ether/hexanes) to give a clear oil (426 mg, 64%).  TLC Rf = 0.65 (25% 
ethyl acetate/hexanes); IR (neat) 2999, 2906, 2851, 1724, 1514, 1229 cm-1;  1H NMR (300 MHz, 
CDCl3) δ 7.27 (d, J = 8.6 Hz, 2H), 6.88 (d, J = 8.7 Hz, 2H), 5.03 (s, 2H), 3.81 (s, 3H), 1.71-2.00 
(m, 15H);  13C NMR (75 MHz, CDCl3) δ 177.6, 159.5, 129.6, 128.8, 113.9, 65.7, 55.3, 40.8, 
38.9, 36.6, 28.1. 
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(S)-4-methoxybenzyl 3,3,3-trifluoro-2-methoxy-2-phenylpropanoate 2.9 
Lit. Ref.:  Yamada, I.; Noyori, R. Organic Letters, 2000, 2, 3425 – 3427. 
In a flame dried 10 mL round bottom flask, (S)-(-)-α-(trifluoromethyl)phenylactic acid (50 mg, 
0.214 mmol) was dissolved in dry dichloromethane (1 mL).  4-methoxybenzyl 2,2,2-
trichloroacetimidate (12 mg, 0.428 mmol) was added.  The reaction was stirred at room 
temperature overnight.  The reaction was taken up in ethyl acetate, washed with sat. aq. sodium 
bicarbonate three times, dried with sodium sulfate and concentrated.  Purification was done with 
flash column chromatography (10% ether/hexanes) to give a clear oil (38 mg, 50%).  TLC Rf = 
0.36 (25% ethyl acetate/hexanes); IR (neat) 2954, 2841, 1747, 1516, 1248, 1174 cm-1;  1H NMR 
(300 MHz, CDCl3) δ 7.26-7.46 (m, 6H), 6.88 (d, J = 8.7 Hz, 2H), 5.29 (q, J = 11.8 Hz, 2H), 3.81 
(s, 3H), 3.51 (s, 3H);  13C NMR (75 MHz, CDCl3) δ 166.5, 160.0, 132.3, 130.5, 129.6, 128.4, 
127.3, 126.8, 125.2, 121.4, 114.0, 67.9, 55.5, 55.3. 
 
 
4-methoxybenzyl 2,2-diphenylacetate 2.10  
In a flame dried 50 mL round bottom flask, diphenylacetic acid (400 mg, 1.88 mmol) was 
dissolved in dry dichloromethane (8 mL).  4-methoxybenzyl 2,2,2-trichloroacetimidate (1.062 g, 
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3.76 mmol) was added.  The reaction was stirred at room temperature for 24 hours.  The reaction 
was taken up in ethyl acetate, washed with sat. aq. sodium bicarbonate three times, dried with 
sodium sulfate and concentrated.  Purification was done with flash column chromatography 
(10% ethyl acetate/hexanes) to give an orange solid (394 mg, 63%).  TLC Rf = 0.35 (25% ethyl 
acetate/hexanes); IR (KBr) 3028, 2956, 2836, 1734, 1612, 1514, 1250, 1145 cm-1;  1H NMR (300 
MHz, CDCl3) δ 7.26-7.34 (m, 11H), 6.90 (d, J = 8.6 Hz, 2H), 5.17 (s, 2H), 5.09 (s, 1H), 3.84 (s, 
3H);  13C NMR (75 MHz, CDCl3) δ 172.5, 159.8, 138.8, 130.2, 128.8, 128.7, 127.9, 127.4, 
114.0, 66.9, 57.2, 55.4. 
 
4-methoxybenzyl 2-acetoxybenzoate 2.11 
In a flame dried 50 mL round bottom flask, acetylsalicylic acid (400 mg, 2.22 mmol) was 
dissolved in dry dichloromethane (9 mL).  4-methoxybenzyl 2,2,2-trichloroacetimidate (1.255 g, 
4.44 mmol) was added.  The reaction was stirred at room temperature for 24 hours.  The reaction 
was taken up in ethyl acetate, washed with sat. aq. sodium bicarbonate three times, dried with 
sodium sulfate and concentrated.  Purification was done with flash column chromatography 
(10% ethyl acetate/hexanes) to give a clear oil (534 mg, 80%).  TLC Rf = 0.69 (25% ethyl 
acetate/hexanes); IR (neat) 2957, 2837, 1769, 1720, 1610, 1515, 1248 1195 cm-1;  1H NMR (300 
MHz, CDCl3) δ 8.04 (d, J = 1.7 Hz, 1H), 7.54 (t, J = 9.0 Hz, 1H), 7.29-7.38 (m, 3H), 7.09 (d, J = 
9.0 Hz, 1H), 6.92 (d, J = 8.7 Hz, 2H), 5.24 (s, 2H), 3.81 (s, 3H), 2.13 (s, 3H);  13C NMR (75 
MHz, CDCl3) δ 169.8, 164.6, 159.9, 150.7, 133.2, 132.1, 130.5, 127.7, 126.1, 123.9, 123.5, 
114.3, 67.0, 55.4, 20.8.  Anal calcd for C17H16O5: C, 67.99; H, 5.37.  Found: C, 67.60; H, 5.17. 
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4-methoxybenzyl cyclopropanecarboxylate 2.12 
In a flame dried 50 mL round bottom flask, cyclopropane carboxylic acid (400 mg, 4.65 mmol) 
was dissolved in dry dichloromethane (19 mL).  4-methoxybenzyl 2,2,2-trichloroacetimidate 
(1.600 g, 5.66 mmol) was added.  The reaction was stirred at room temperature for 24 hours.  
The reaction was taken up in ethyl acetate, washed with sat. aq. sodium bicarbonate three times, 
dried with sodium sulfate and concentrated.  Purification was done with flash column 
chromatography (10% ethyl acetate/hexanes) to give a clear oil (493 mg, 51%).  TLC Rf = 0.53 
(25% ethyl acetate/hexanes); IR (neat) 3011, 2956, 2836, 1724, 1613, 1515, 1249, 1166 cm-1;  1H 
NMR (300 MHz, CDCl3) δ 7.30 (d, J= 8.6 Hz, 2H), 6.88 (d, J= 8.7 Hz, 2H), 5.05 (s, 2H), 3.78 (s, 
3H), 1.59-1.67 (m, 1H), 0.94-1.08 (m, 2H), 0.78-0.91 (m, 2H);  13C NMR (75 MHz, CDCl3) δ 
174.7, 159.6, 130.1, 128.3, 113.9, 66.1, 55.2, 13.0, 8.5. 
 
 
4-methoxybenzyl 3-(2,4-dichlorobenzyloxy)thiophene-2-carboxylate 2.13 
In a flame dried 50 mL round bottom flask, 3-(2,4-dichlorobenzyloxy)thiophene-2-carboxylic 
acid (400 mg, 1.32 mmol) was dissolved in dry dichloromethane (3 mL).  4-methoxybenzyl 
2,2,2-trichloroacetimidate (746 mg, 2.64 mmol) was dissolved in dry dichloromethane (3 mL) 
and added to the round bottom flask.  The reaction was stirred at room temperature for 24 hours.  
43 
 
The reaction was taken up in ethyl acetate, washed with sat. aq. sodium bicarbonate three times, 
dried with sodium sulfate and concentrated.  Purification was done with flash column 
chromatography (10% ethyl acetate/hexanes) to give a white solid (153 mg, 27%). mp = ;  TLC 
Rf = 0.58 (25% ethyl acetate/hexanes); IR (neat) 2954, 1682, 1588, 1544, 1431, 1384, 1248 cm
-1; 
1H NMR (300 MHz, CDCl3) δ 7.53 (d, J = 8.4 Hz, 1H), 7.34-7.43 (m, 3H), 7.15 (d, J = 6.0 Hz, 
1H), 6.89-6.92 (m, 3H), 5.30 (s, 2H), 5.71 (s, 2H), 3.81 (s, 3H). 
 
 
4-methoxybenzyl 2-(diphenylphosphino)benzoate 2.14 
In a flame dried 50 mL round bottom flask, 2-(diphenylphosphino)benzoic acid (400 mg, 1.31 
mmol) was dissolved in dry dichloromethane (2.5 mL).  4-methoxybenzyl 2,2,2-
trichloroacetimidate (746 mg, 2.64 mmol) was dissolved in dry dichloromethane (2.5 mL) and 
added to the round bottom flask.  The reaction was stirred at room temperature for 24 hours.  The 
reaction was taken up in ethyl acetate, washed with sat. aq. sodium bicarbonate three times, dried 
with sodium sulfate and concentrated.  Purification was done with flash column chromatography 
(1:1 ethyl acetate/hexanes) to give a clear oil (139 mg, 25%).  TLC Rf = 0.26 (60% ethyl 
acetate/hexanes); IR (neat) 3056, 1727, 1612, 1514, 1248, 1118 cm-1; 1H NMR (300 MHz, 
CDCl3) δ 7.86-7.90 (m, 1H), 7.39-7.68 (m, 13H), 7.07 (d, J = 14.2 Hz, 2H), 6.78 (d, J = 9.0, 2H), 
4.90 (s, 2H), 3.78 (s, 3H). 
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benzhydryl 3,3-dimethylbutanoate 2.17 
In a flame dried 50 mL round bottom flask, tert-butylacetic acid (0.33 mL, 2.58 mmol) was 
dissolved in dry dichloromethane (10 mL).  Benzhydryl 2,2,2-trichloroacetimidate (1.101 g, 3.35 
mmol) was added.  The reaction was stirred at room temperature for 24 hours.  The reaction was 
concentrated.  Purification was done with flash column chromatography (1% ethyl 
acetate/hexanes) to give a clear oil (0.669 g, 92%).  TLC Rf = 0.79 (10% ethyl acetate/hexanes); 
1H NMR (300 MHz, CDCl3): δ 7.26-7.37 (m, 9H), 6.89 (s, 1H), 2.32 (s, 2H), 0.99 (s, 9H);  
13C 
NMR (75 MHz, CDCl3):  δ 171.4, 140.6, 128.6, 127.9, 127.4, 76.7, 48.2, 31.1, 29.8.  Anal. Calcd 
for C19H22O2: C, 80.82; H, 7.85. Found: C, 81.11; H, 8.03.  
 
 
benzhydryl-1-adamantanoate 2.19 
In a flame dried 25 mL round bottom flask, adamantane-1-carboxylic acid (0.300 g, 1.66 mmol) 
was dissolved in dry dichloromethane (7 mL).  Benzhydryl 2,2,2-trichloroacetimidate (0.710 g, 
2.16 mmol) was added.  The reaction was stirred at room temperature for 24 hours.  The reaction 
was concentrated.  Purification was done with flash column chromatography (1% ethyl 
acetate/hexanes) to give an orange solid (0.177 g, 31%).  TLC Rf = 0.64 (10% ethyl 
acetate/hexanes); 1H NMR (300 MHz, CDCl3) δ 7.23-7.36 (m, 16H), 6.83 (s, 1H), 2.03 (bs, 4H), 
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1.96 (bs, 9H), 1.73 (bs, 9H);  13C NMR (75 MHz, CDCl3) δ 176.5, 142.4, 140.9, 128.6, 128.5, 
127.9, 127.6, 127.4, 127.1, 80.1, 76.3, 40.9, 39.0, 36.7, 28.1. Anal. Calcd for C24H26O2: C, 
83.20; H, 7.56. Found: C, 83.17; H, 7.85. 
General Procedure for Forming Sulfides from Trichloroacetimidates: 
The thiol was placed in a dry round bottom flask and dissolved in anhydrous THF (or toluene) to 
a concentration of 0.2 M. The trichloroacetimidate (1.2 equiv) was then added and the reaction 
was warmed to reflux. After 18 hours the reaction was cooled to room temperature and 
concentrated under reduced pressure. The residue was then pre-adsorbed on silica gel and 
purified by column chromatography. Alternatively, the residue can be dissolved in ethyl acetate, 
washed with 2M aq. NaOH (3x), dried (Na2SO4) and concentrated (this workup removes the 
trichloroacetamide byproduct). For some sulfides this workup provided analytically pure 
material, in others the residue is purified by silica gel chromatography to provide the pure sulfide 
product. 
 
5-[(3-Methyl-2-butenyl)thio]-1-phenyl-1H-tetrazole 2.21.  
Cream colored solid (0.250 g, 98%). mp =38.6-39.9°C; TLC Rf = 0.72 (30% ethyl acetate /70% 
hexanes); IR (neat) 3062, 3015, 2981, 2928, 2895 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.61-7.55 
(m, 5H), 5.44-7.37 (m, 1H), 4.04 (d, J = 8.0 Hz, 2H), 1.73 (s, 6H) . Anal calcd for C12H14N4S: C, 
58.51; H, 5.73, N, 22.74. Found: C, 58.29; H, 5.54; N, 22.39. 
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1-Phenyl-5-[[(2E)-3-phenyl-2-propen-1-yl]thio]-1H-tetrazole 2.22.  
Lit. Ref.: Han, X.; Wu, J. Org. Lett. 2010, 12, 5780-5782. 
Yellow oil (0.264 g, 95%). TLC Rf = 0.63 (30% ethyl acetate /70% hexanes); 
1H NMR (400 
MHz, CDCl3) δ 7.61-7.55 (m, 5H), 7.39- 7.27 (m, 5H), 6.72 (d, J = 15.6 Hz, 1H), 6.41-6.31 (m, 
1H), 4.23 (d, J = 8.8 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 153.9, 136.2, 135.4, 133.8, 130.3, 
130.0, 128.8, 128.3, 126.7, 124.0, 122.6, 36.1. 
 
5-(Isopropylthio)-1-phenyl-1H-tetrazole 2.23.  
Lit. Ref.: Marti, C.; Carreira, E. M. J. Am. Chem. Soc. 2005, 127, 11505-11515. 
Yellow oil (0.689 g, 38%). TLC Rf = 0.64 (35% DCM /65% hexanes); 
1H NMR (400 MHz, 
CDCl3) δ 7.58-7.52 (m, 5H), 3.42 (heptet, J = 6.5 Hz, 1H), 1.51 (d, J = 6.5 Hz, 6H); 
13C NMR 
(75 MHz, CDCl3) δ 154.1, 133.7, 130.1, 129.7, 124.0, 39.8, 23.3. 
 
General Procedure for the Formation of DPM Ethers from Alcohols under Thermal 
Conditions: 
The alcohol was placed in a 25 mL flame dried round bottom flask and dissolved in anhydrous 
toluene to a concentration of 0.25 M. The trichloroacetimidate (1.2 equiv) was added and the 
reaction warmed to reflux. After 18 hours, the reaction was cooled to room temperature and 
concentrated under reduced pressure. The residue was pre-adsorbed on silica gel and purified by 
silica gel column chromatography. The residue can be dissolved in ethyl acetate, washed with 
2M aq. NaOH (3x), dried (Na2SO4) and concentrated (this workup removes the 
trichloroacetamide byproduct). 
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Octadecyloxydiphenylmethane 2.35.   
White solid (0.273 g, 85%). mp = 47-48 °C;  TLC Rf = 0.80 (10% ethyl acetate/hexanes); IR (solid 
film from CH2Cl2) 3027, 2923, 2852, 1493, 1453, 1097 cm
-1; 1H NMR (300 MHz, CDCl3) δ 7.21-
7.37 (m, 10H), 5.33 (s, 1H), 3.44 (t, J = 6.6 Hz, 2H), 1.60-1.67 (m, 2H), 1.26 (m, 30H), 0.88 (t, J 
= 6.3 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 142.9, 128.5, 127.5, 127.2, 83.8, 69.4, 32.2, 30.1, 
29.94, 29.91, 29.87, 29.85, 29.7, 29.6, 26.5, 22.9, 14.3 (several signals in the aliphatic region were 
not resolved). Anal calcd for C31H48O: C, 85.26; H, 11.08. Found: C, 85.18; H, 11.13. 
 
 
Benzyloxydiphenylmethane 2.36.  
Lit. Ref.: Xu, Q.; Xie, H.; Chen, P.; Yu, L.; Chen, J.; Hu, X. Green Chem. 2015, 17, 2774-2779. 
Clear oil (0.238 g, 94%). TLC Rf = 0.92 (25% ethyl acetate/hexanes); 
1H NMR (300 MHz, CDCl3) 
δ 7.24-7.42 (m, 15H), 5.46 (s, 1H), 4.56 (s, 2H); 13C NMR (75 MHz, CDCl3) δ 142.4, 138.6, 128.6, 
128.6, 127.9, 127.72, 127.65, 127.3, 82.7, 70.7.  
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(4-Methoxybenzyloxy)diphenylmethane 2.37.  
Lit. Ref.: Kalutharage, N.; Yi, C. S. Org. Lett. 2015, 17, 1778-1781. 
Clear oil (0.314 g, 71%). TLC Rf = 0.50 (10% ethyl acetate/hexanes); 
1H NMR (300 MHz, CDCl3) 
δ 7.24-7.41 (m, 12H), 6.91 (d, J = 8.7 Hz, 2H), 5.45 (s, 1H), 4.50 (s, 2H), 3.83 (s, 3H); 13C NMR 
(100 MHz, CDCl3) δ 159.3, 142.4, 130.6, 129.5, 128.5, 127.6, 127.3, 113.9, 82.2, 70.3, 55.4.  
 
 
(((4-Nitrobenzyl)oxy)methylene)dibenzene 2.39.  
Off-white solid (0.460 g, 88%). mp = 62-64 °C (DCM); TLC Rf = 0.59 (40% DCM/60% hexanes); 
IR (solid film from CH2Cl2) 3062, 3028, 2922, 2857, 1493, 1347, 1288 cm
-1; 1H NMR (300 MHz, 
CDCl3) δ 8.19 (d, J = 8.7 Hz, 2H), 7.52 (d, J = 8.1 Hz, 2H), 7.25-7.40 (m, 10H), 5.46 (s, 1H), 4.62 
(s, 2H); 13C NMR (75 MHz, CDCl3) δ 147.4, 146.1, 141.6, 128.6, 127.8, 127.7, 127.0, 123.6, 83.5, 
69.5. Anal calcd for C20H17NO3: C, 77.22; H, 5.37; N, 3.49. Found: C, 77.20; H, 5.31; N, 3.44. 
 
 
Cinnamyloxydiphenylmethane 2.43.  
Lit. Ref.:  Zhang, W.; Haight, A. R.; Hsu, M. C. Tetrahedron Lett. 2002, 43, 6575-6578. 
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White solid (0.395 g, 88%). mp = 55-57 °C; TLC Rf = 0.58 (25% ethyl acetate/hexanes); 
1H NMR 
(300 MHz, CDCl3) δ 7.23-7.42 (m, 15H), 6.63 (d, J = 15.9 Hz, 1H), 6.32-6.41 (m, 1H), 5.51 (s, 
1H), 4.20 (dd, J = 6.0, 1.5 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 142.3, 136.9, 132.3, 128.6, 
128.5, 127.7, 127.5, 127.1, 126.6, 126.3, 82.8, 69.4. 
 
 
Diphenyl(prop-2-ynyloxy)methane 2.47.  
Lit. Ref.: Louvel, J.; Carvalho, J. F. S.; Yu, Z.; Soethoudt, M.; Lenselink, E. B.; Klaasse, E.; 
Brussee, J.; Ijzerman, A. P. J. Med. Chem. 2013, 56, 9427-9440. 
Yellow oil (0.384 g, 97%). TLC Rf = 0.86 (10% ethyl acetate/hexanes); 
1H NMR (300 MHz, 
CDCl3) δ 7.24-7.40 (m, 10H), 5.68 (s, 1H), 4.17 (d, J = 2.4 Hz, 2H), 2.46 (t, J = 2.4 Hz, 1H);
 13C 
NMR (100 MHz, CDCl3) δ 141.3, 128.6, 127.9, 127.5, 81.8, 79.9, 74.8, 56.0. 
 
 
((Cyclohexyloxy)methylene)dibenzene 2.44.  
Lit. Ref.:  Bhaskar, G.; Solomon, M.; Babu, G.; Muralidharan, D.; Perumal, P. T. Indian J. 
Chem., Sect. B. 2010, 49B, 795-801. 
Clear oil (0.494 g, 93%). TLC Rf = 0.68 (10% ethyl acetate/hexanes); 
1H NMR (300 MHz, CDCl3) 
δ 7.24-7.40 (m, 10H), 5.58 (s, 1H), 3.35-3.44 (m, 1H), 1.93 (dd, J = 9.0, 6.0 Hz, 2H), 1.76-1.82 
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(m, 2H), 1.41-1.58 (m, 3H), 1.26 (q, J = 8.3 Hz, 3H); 13C NMR (75MHz, CDCl3) δ143.3, 128.4, 
127.31, 127.26, 80.1, 75.1, 32.5, 26.0, 24.2. 
 
 
((1-Phenylethoxy)methylene)dibenzene 2.38.  
Lit. Ref.: Sciebura, J.; Gawronski, J. Tetrahedron: Asymmetry 2013, 24, 683-688. 
Clear oil (0.434 g, 92%). TLC Rf = 0.85 (10% acetone/hexanes); 
1H NMR (300 MHz, CDCl3) δ 
7.20-7.41 (m, 15H), 5.31 (s, 1H), 4.51 (q, J = 6.6 Hz, 1H), 1.53 (d, J = 6.3 Hz, 3H); 13C NMR (75 
MHz, CDCl3) δ 143.9, 143.0, 142.2, 128.7, 128.4, 128.3, 127.73, 127.70, 127.67, 127.3, 127.1, 
126.7, 80.2, 75.1, 24.5. 
 
 
((tert-Pentyloxy)methylene)dibenzene 2.45.  
Lit. Ref.:  Buckley, A.; Chapman, N. B.; Dack, M. R. J.; Shorter, J.; Wall, H. M. J. Chem. Soc., B 
1968, 631-638. 
Clear oil (0.489 g, 85%). TLC Rf = 0.92 (10% ethyl acetate/hexanes); 
1H NMR (300 MHz, CDCl3) 
δ 7.41 (d, J = 6.9 Hz, 4H), 7.33 (t, J = 7.2 Hz, 4H), 7.20-7.26 (m, 2H), 5.60 (s, 1H), 1.62 (q, J = 
7.5 Hz, 2H), 1.17 (s, 6H), 0.91 (t, J = 7.5 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 145.6, 128.3, 
127.0, 126.9, 76.9, 75.6, 34.8, 26.1, 8.9. 
51 
 
 
 
1-(Benzhydryloxy)adamantane 2.46.  
Orange solid (0.383 g, 92%). mp = 64-66 °C; TLC Rf = 0.71 (10% ethyl acetate/hexanes); IR (solid 
film from CH2Cl2) 3025, 2905, 2850, 1492, 1451, 1354, 1082 cm
-1; 1H NMR (300 MHz, CDCl3) 
δ 7.20-7.39 (m, 10H), 5.80 (s, 1H), 2.14 (s, 3H), 1.83 (bs, 6H), 1.62 (bs, 6H); 13C NMR (100 MHz, 
CDCl3) δ 145.3, 128.2, 127.2, 126.9, 74.4, 73.8, 43.0, 36.6, 30.8. Anal calcd for C23H26O: C, 86.75; 
H, 8.23. Found: C, 86.72; H, 8.18. 
 
 
2-((Benzhydryloxy)methyl)-3-phenyloxirane 2.51.  
Lit. Ref.: Vidal-Ferran, A.; Moyano, A.; Pericas, M. A.; Riera, A. J. Org. Chem. 1997, 62, 4970-
4982. 
Clear oil (0.255 g, 65%) TLC Rf = 0.50 (10% ethyl acetate/hexanes); 
1H NMR (300 MHz, CDCl3) 
δ 7.25-7.44 (m, 15H), 5.53 (s, 1H), 3.86 (dd, J = 11.5, 3.1 Hz, 1H), 3.80 (d, J = 2.0 Hz, 1H) 3.66 
(dd, J = 5.3, 11.5 Hz, 1H), 3.29-3.32 (m, 1H). 13C NMR (100 MHz, CDCl3) δ 141.99, 141.94, 
137.1, 128.7, 128.6, 128.4, 127.8, 127.77, 127.5, 127.3, 127.2, 125.9, 84.1, 68.9, 61.4, 56.1. 
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(2-(Benzhydryloxy)ethyl)trimethylsilane 2.53.   
Pale yellow oil (0.368 g, 79%). TLC Rf = 0.56 (15% DCM/5% triethylamine/ 80% hexanes); IR 
(solid film from CH2Cl2) 3087, 3063, 3029, 2953, 2892, 1452, 1317, 1249 cm
-1; 1H NMR (400 
MHz, CDCl3) δ 7.36 (dd, J = 6.3, 1.2 Hz, 4H), 7.30 (t, J = 6.6 Hz, 4H), 7.22-7.25 (m, 2H), 5.35 (s, 
1H), 3.56 (t, J = 6.0 Hz, 2H), 1.03 (t, J = 6.0 Hz, 2H), 0.00 (s, 9H); 13C NMR (100 MHz, CDCl3) 
δ 144.0, 129.6, 128.5, 128.2, 84.6, 67.6, 19.7, 0.0; Anal calcd for C18H24OSi: C, 76.00; H, 8.50; 
Found: C, 75.77; H, 8.62. 
 
 
2-(Benzhydryloxy)isoindoline-1,3-dione 2.49.  
Lit. Ref.: Reddy, C. R.; Radhika, L.; Kumar, T. P.; Chandrasekhar, S. Eur. J. Org. Chem. 2011, 
2011, 5967-5970. 
Yellow solid (0.323 g, 80%). mp = 160-162 °C; TLC Rf = 0.29 (10% acetone/hexanes); 
1H NMR 
(300 MHz, CDCl3) δ 7.66-7.76 (m, 4H), 7.52-7.56 (m, 4H), 7.29-7.39 (m, 6H), 6.53 (s, 1H); 
13C 
NMR (100 MHz, CDCl3) δ 163.8, 137.9, 134.4, 128.9, 128.8, 128.5, 128.4, 123.4, 89.7.  
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(S)-Benzyl 3-(benzhydryloxy)-2-(((benzyloxy)carbonyl)amino)propanoate 2.55.  
Clear oil (0.273 g, 91%). [α]𝐷
21.6 -12.5 (c 1.26, CHCl3); TLC Rf = 0.18 (10% ethyl acetate/hexanes); 
IR (solid film from CH2Cl2) 3434, 3341, 3062, 3030, 2949, 2876, 1722, 1498, 1339, 1197, 1067 
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.07-7.30 (m, 20H), 5.63 (d, J = 12.0 Hz, 1H), 5.19 (s, 1H), 
5.12 (d, J = 4.0 Hz, 2H), 5.04 (s, 2H), 4.49 (dt, J = 2.8 Hz, 1H), 3.84 (dd, J = 9.4, 2.8 Hz, 1H), 
3.60 (dd, J = 9.4, 3.1 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ170.3, 156.1, 141.6, 141.4, 136.4, 
135.4, 128.7, 128.65, 128.6, 128.5, 128.4, 128.3, 128.2, 127.7, 127.0, 126.9, 84.2, 69.0, 67.4, 67.2, 
54.8 . (note: two signals in the aromatic region were not resolved.) Anal calcd for C31H29NO5: C, 
75.13; H, 5.90; N, 2.83. Found: C, 74.94; H, 5.97; N, 3.00. Chiral HPLC analysis: Chiralcel OD 
(heptane/2-PrOH = 90/10, 1.0 mL/min, 254 nm, 25 °C): t(S enantiomer) = 16.7 min, t(R enantiomer) = 23.9 
min. 
 
 
Methyl 2,3,4-Tri-O-benzyl-6-O-diphenylmethyl-α-D-glucopyranoside 2.52.  
Lit. Ref.: Ali, I. A. I.; El Ashry, E. S. H.; Schmidt, R. R. Eur. J. Org. Chem. 2003, 4121-4131. 
Clear colored oil (0.750 g, 73%). TLC Rf = 0.43 (15% ethyl acetate/85% hexanes); 
1H NMR (300 
MHz, CDCl3) δ 7.55-7.18 (m, 25 H), 5.50 (s, 1H), 5.13 (d, J = 10.8 Hz, 1H), 4.98 (t, J = 11.1 Hz, 
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2H), 4.93 (d, J = 12.0 Hz, 1H), 4.82 (d, J = 11.7 Hz, 1H), 4.80 (d, J = 3.6 Hz, 1H), 4.68 (d, J = 
11.1 Hz, 1H), 4.16 (t, J = 9.3 Hz, 1H), 3.89-3.99 (m, 1H), 3.77-3.84 (m, 3H), 3.72 (dd, J = 3.6, 
9.6 Hz, 1H), 3.49 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 142.2, 142.1, 138.8, 138.3, 138.2, 128.5, 
128.4, 128.36, 128.1, 127.9, 127.8, 127.7, 127.5, 127.4, 127.2, 126.9, 98.1, 84.1, 82.3, 80.1, 78.0, 
75.9, 75.1, 73.4, 70.3, 67.9, 55.1. 
 
 
(3S,5S,8R,9S,10S,13R,14S,17R)-3-(Benzhydryloxy)-10,13-dimethyl-17-((R)-6-
methylheptan-2-yl)hexadecahydro-1H-cyclopenta[a]phenanthrene 2.48.  
White solid (0.374 g, 87%). [α]𝐷
21.6 +12.4 (c 1.04, CHCl3); mp = 127-129 °C; TLC Rf = 0.74 (10% 
ethyl acetate/hexanes); IR (solid film from CH2Cl2) 3027, 2930, 2865, 1493, 1452, 1381, 1062 cm
-
1; 1H NMR (300 MHz, CDCl3) δ 7.16-7.34 (m, 10H), 5.54 (s, 1H), 3.28-3.38 (m, 1H), 0.63-1.92 
(m, 46H); 13C NMR (75 MHz, CDCl3) δ 143.3, 128.4, 127.4, 127.3, 80.3, 76.5, 56.7, 56.5, 54.6, 
45.0, 42.8, 40.3, 39.7, 37.2, 36.4, 36.0, 35.95, 35.7, 35.3, 32.3, 29.1, 28.7, 28.5, 28.2, 24.4, 24.0, 
23.0, 22.8, 21.4, 18.9, 12.5, 12.3. Anal calcd for C40H58O: C, 86.58; H, 10.54. Found: C, 86.59; H, 
10.68. 
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Ethyl 3-(benzhydryloxy)-3-phenylpropanoate 2.50.  
White solid (0.178 g, 96%). mp = 73-74 °C; TLC Rf = 0.53 (10% ethyl acetate/hexanes); IR (solid 
film from CH2Cl2) 3061, 3028, 2980, 1736, 1493, 1453, 1268, 1172, 1052 cm
-1; 1H NMR (300 
MHz, CDCl3) δ 7.19-7.40 (m, 15H), 5.24 (s, 1H), 4.81 (ddd, J = 1.3, 4.9, 9.0 Hz, 1H), 4.00-4.23 
(m, 2H), 2.96 (ddd, J = 1.4, 9.0, 14.7 Hz, 1H), 2.65 (ddd, J = 1.2, 4.9, 14.7 Hz, 1H), 1.21 (td, J = 
1.1, 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 170.8, 142.8, 141.3, 140.7, 128.8, 128.6, 128.3, 
128.2, 128.0, 127.9, 127.24, 127.16 126.7, 80.11, 75.7, 60.6, 44.0, 14.3. Anal calcd for C24H24O3: 
C, 79.97; H, 6.71. Found: C, 79.96; H, 6.88. 
 
 
(R)-Ethyl 2-(benzhydryloxy)propanoate 2.54.  
Lit. Ref.: Steinbeck, M.; Frey, G. D.; Schoeller, W. W.; Herrmann, W. A. J. Organomet. Chem. 
2011, 696, 3945-3954. 
Clear oil (0.434 g, 90%). [α]𝐷
21.6 -103.8 (c 1.04, DCM); TLC Rf = 0.57 (10% ethyl 
acetate/hexanes); 1H NMR (300 MHz, CDCl3) δ 7.26-7.41 (m, 10H), 5.57 (s, 1H), 4.16-4.28 (m, 
2H), 4.08 (q, J = 6.0 Hz, 1H), 1.49 (d, J = 9.0 Hz, 3H), 1.30 (t, J = 9.0 Hz, 3H); 13C NMR (100 
MHz, CDCl3) δ 173.6, 142.1, 141.1, 128.7, 128.4, 128.0, 127.7, 127.6, 127.5, 82.8, 72.7, 61.0, 
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19.0, 14.4. Chiral HPLC analysis: Chiralcel OD (heptane/2-PrOH = 99/1, 1.0 mL/min, 254 nm, 25 
°C): t(R enantiomer) = 5.3 min, t(S enantiomer) = 5.8 min. 
 
 
((4-Methoxyphenoxy)methylene)dibenzene 2.40.  
Lit. Ref.: Bordwell, F. G.; Harrelson, J. A., Jr. J. Org. Chem. 1989, 54, 4893-4898. 
Orange solid (0.424 g, 91%). mp = 84-85 °C; TLC Rf = 0.42 (10% acetone/hexanes); 
1H NMR 
(300 MHz, CDCl3) δ 7.26-7.43 (m, 10H), 6.88 (d, J = 9.1 Hz, 2H), 6.75 (d, J = 9.2 Hz, 2H), 6.11 
(s, 1H), 3.73 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 154.2, 152.4, 141.7, 128.7, 127.8, 127.1, 
117.4, 114.7, 82.8, 55.7. 
 
 
((4-Nitrophenoxy)methylene)dibenzene 2.41.  
Lit. Ref.:  Maslak, P.; Guthrie, R. D. J. Am. Chem. Soc. 1986, 108, 2628-2636. 
Pale yellow colored solid (0.310 g, 61%). mp = 157-158 °C; TLC Rf = 0.36 (10% ethyl acetate/90% 
hexanes); 1H NMR (300 MHz, CDCl3) δ 8.13 (d, J = 9.0 Hz, 2H), 7.28-7.42 (m, 10H), 7.02 (d, J 
= 9.3 Hz, 2H), 6.31 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 162.9, 141.6, 139.8, 128.8, 128.3, 126.7, 
125.8, 115.9, 82.5. 
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Methyl 3-(benzhydryloxy)thiophene-2-carboxylate 2.42.  
White solid, (0.280 g, 53%). mp = 105-106 °C; TLC Rf = 0.3 (10% ethyl acetate/90% hexanes); 
IR (solid film from CH2Cl2) 3061, 3028, 2948, 1711, 1538, 1228, 1062 cm
-1; 1H NMR (400 MHz, 
CDCl3) δ 7.53 (d, J = 7.6 Hz, 4H), 7.35 (t, J = 7.2 Hz, 4H), 7.25–7.28 (m, 3H), 6.74 (d, J = 5.6 Hz, 
1H), 6.27 (s, 1H), 3.90 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 162.4, 160.1, 141.2, 130.4, 128.9, 
128.1, 126.7, 118.7, 111.6, 85.0, 51.8. Anal calcd for C19H16O3S: C, 70.35; H, 4.97; Found: C, 
70.26; H, 5.02. 
 
1-methoxy-4-((1-phenylethoxy)methyl)benzene 2.66 
Lit. Ref.:  Bartels, B.; Hunter, R.  J. Org. Chem., 1993, 58, 6756–6765. 
In a 10 mL flame dried round bottom flask, 1-phenylethanol (0.366 g, 3.0 mmol) was dissolved 
in anhydrous trifluorotoluene (3 mL).  PMB imidate (1.690g, 6.0 mmol) was added to the flask.  
The reaction refluxed for 20 hours.  The reaction was concentrated.  Purification was done using 
column chromatography (10% ethyl acetate/hexanes) followed by column chromatography (50% 
CH2Cl2) to give product as a clear colorless oil (0.477 g, 67%). 
TLC Rf = 0.52 (10% ethyl acetate/90% hexanes); 
1H NMR (300 MHz, CDCl3) δ 7.35-7.20 (m, 
6H), 6.85 (d, J = 8.7 Hz, 2H), 4.46 (q, J = 6.6 Hz, 1H), 4.23 (dd, J = 11.4, 46.8 Hz, 2H), 3.75 (s, 
3H), 1.45 (d, J = 6.3 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 159.2, 143.9, 130.8, 129.4, 128.6, 
127.5, 126.4, 113.9, 77.0, 55.3, 24.3; 
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4-methoxybenzyl benzyl ether 2.63. 
Lit. Ref.:  Baltzly, R.; Buck, J. S. J. Am. Chem. Soc., 1943, 65, 1984–1992 
81% yield, clear colored oil. TLC Rf = 0.54 (20% ethyl acetate/80% hexanes); 
1H NMR (400 
MHz, CDCl3) δ 7.34-7.23 (m, 7 H), 6.87 (d, J = 8.4 Hz, 2 H), 4.51 (s, 2 H), 4.48 (s, 2 H), 3.77 (s, 
3 H); 13C NMR (100 MHz, CDCl3) δ 159.1, 138.3, 130.3, 129.3, 128.3, 127.7, 127.5, 113.7, 
71.6, 55.2.  
 
bis(4-methoxybenzyl)ether 2.64.  
Lit. Ref.:  Felix, D., Gschwend-Steen, K.; Wick, A. E.; Eschenmoser, A. HCA, 1969, 1030–1042.  
78% yield, clear colored oil.  TLC Rf = 0.50 (20% acetone/80% hexanes); 
1H NMR (400 MHz, 
CDCl3) δ 7.27 (d, J = 8.8 Hz, 4 H), 6.87 (d, J = 8.8 Hz, 4 H), 4.50 (s, 4 H), 3.78 (s, 6 H); 
13C 
NMR (100 MHz, CDCl3) δ 159.1, 130.4, 129.3, 113.7, 71.4, 55.2. 
 
 
1-methoxy-4-(4-nitro-benzyloxymethyl)-benzene 2.65.  
85% yield, dark yellow colored oil. TLC Rf = 0.45 (10% acetone/90% hexanes); IR (neat) 3109, 
3076, 3003, 2935, 2838, 1561, 1342, 1302, 1246; 1H NMR (400 MHz, CDCl3) δ 8.21 (d, J = 2 
Hz, 2 H), 7.51 (d, J = 8.8 Hz, 2 H), 7.26 (d, J = 2 Hz, 2 H), 6.90 (d, J = 8.8 Hz, 2 H), 4.61 (s, 2 
H), 4.55 (s, 2 H), 3.81 (s, 3 H); 13 C NMR (100 MHz, CDCl3) δ 159.5, 147.3, 146.1, 129.6, 
59 
 
129.5, 129.3, 127.8, 123.6, 114.4, 113.9, 72.5, 70.5, 55.3, 44.9; Anal. Calcd for C15H15NO4: C, 
65.92; H, 5.53; N, 5.13. Found: C, 65.80, H, 5.41, N, 5.00. 
 
 
N-(4-methoxybenzyloxy)phthalimide.  
Lit. Ref.:  Ramsay, S. L.; Freeman, C.; Grace, P. B.; Redmond, J. W.; MacLeod, J. K. 
Carbohydrate Research. 333. 59-71.  
58% yield, white colored solid. mp = 134.9-136.3°C (ethyl acetate); TLC Rf = 0.28, 0.57 (20% 
ethyl acetate/80% hexanes); 1H NMR (300 MHz, CDCl3) δ 7.82-7.71 (m, 4 H) 7.45 (d, J = 8.4 
Hz, 2 H), 6.88 (d, J = 8.4 Hz, 2 H), 5.15 (s, 2 H), 3.80 (s, 3 H); 13C NMR (75 MHz, CDCl3) δ 
163.5, 160.4, 134.3, 131.6, 128.8, 125.8, 123.4, 113.9, 79.4, 55.2.  
 
(4-Methoxyphenyl)methyl propargyl ether 2.67. 
Lit. Ref.:  Marshall, J. A.; Robinson, E. D.; Zapata, A. J. Org. Chem., 1989, 54, 5854–5855 
82% yield, Clear oil. TLC Rf = 0.41 (10% Ethyl acetate/90% hexanes); 
1H NMR (400 MHz, 
CDCl3) δ 7.32 (d, J = 8.4 Hz, 2 H), 6.93 (d, J = 1.8 Hz, 2 H), 4.57 (s, 2 H), 4.17 (d, J = 2.4 Hz, 2 
H), 3.82 (s, 3 H), 4.55 (s, 2 H), 2.52 (d, J = 2.4 Hz, 1 H). 
 
1-((4-methoxybenzyl)oxy)-2-nitrobenzene 2.70. 
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76% yield, yellow oil. TLC Rf = 0.30 (10% ethyl acetate/90% hexanes); 
1H NMR (400 MHz, 
CDCl3) δ 7.83 (dd, J = 1.6, 8.1 Hz, 1H), 7.49 (ddd, J = 1.7, 7.5, 8.4 Hz, 1H), 7.38 (d, J = 8.6 Hz, 
2H), 7.14 (dd, J = 1.0, 8.5 Hz, 1H), 7.02 (td, J = 0.9, 7.6 Hz, 1H), 6.91 (d, J = 8.7 Hz, 2H), 5.16 
(s, 2H), 3.81 (s, 3H).    
 
(2-((4-methoxybenzyl)oxy)ethyl)trimethylsilane 2.74. 
68% yield, red oil. TLC Rf = 0.76 (10% ethyl acetate/90% hexanes); 
1H NMR (300 MHz, 
CDCl3) δ 7.25 (d, J = 8.4 Hz, 2H),  6.86 (d, J = 8.1 Hz, 1H), 4.40 (s, 2H), 3.78 (s, 3H), 3.54 (td, J 
= 0.9, 8.1 Hz, 2H), 0.97 (td, J = 0.9, 8.1 Hz, 2H), 0.00 (s, 9H).    
 
(E)-1-((cinnamyloxy)methyl)-4-methoxybenzene 2.62. 
Lit. Ref.:  Charette, A. B. Synlett 2002, 176-178.    
52% yield, yellow oil. TLC Rf = 0.70 (25% ethyl acetate/75% hexanes); 
1H NMR (400 MHz, 
CDCl3) δ 7.40 (d, J = 7.2 Hz, 2H), 7.34-7.30 (m, 4H), 7.25 (d, J = 6.3 Hz, 1H), 6.90 (d, J = 8.6 
Hz, 2H), 6.63 (d, J = 16.0 Hz, 1H), 6.33 (dt, J = 6.0, 15.9 Hz, 1H), 4.52 (s, 2H), 4.18 (dd, J = 1.4, 
6.0 Hz, 2H), 3.82 (s, 3H).    
 
1-methoxy-4-((octadecyloxy)methyl)benzene 2.60. 
Lit. Ref.: Kurosu, M. Synthesis 2009, 3633-3641. 
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96 % yield, white solid. mp = 45.6-46.5°C (dichloromethane). TLC Rf = 0.82 (10% ethyl 
acetate/90% hexanes); 1H NMR (400 MHz, CDCl3) δ 7.26 (d, J = 8.8 Hz, 2H), 6.87 (d, J = 8.7 
Hz, 2H), 4.42 (s, 2H), 3.79 (s, 3H), 3.43 (t, J = 6.7 Hz, 2H), 1.63-1.56 (m, 2H), 1.36-1.25 (m, 
34H), 0.88 (t, J = 6.6 Hz, 3H).    
 
ethyl 3-((4-methoxybenzyl)oxy)-3-phenylpropanoate 2.77. 
61% yield, clear oil. TLC Rf = 0.47 (10% ethyl acetate/90% hexanes); 
1H NMR (300 MHz, 
CDCl3) δ 7.39-7.29 (m, 5H), 7.19 (d, J = 8.7 Hz, 2H), 6.85 (d, J = 8.7 Hz, 2H), 4.83 (q, J = 5.1 
Hz, 1H), 4.38 (d, J = 11.4 Hz, 1H), 4.23 (d, J = 11.1 Hz, 1H), 4.17-4.06 (m, 2H), 3.80 (s, 3H), 
2.85 (dd, J = 9.0, 15.0 Hz, 1H), 2.59 (dd, J = 4.8, 15.3 Hz, 1H), 1.20 (t, J = 7.2 Hz, 3H). 
 
3-[(4-Methoxybenzyl)oxy]propan-1-ol 2.84. 
Lit. Ref.: Adje, N.; Breuilles, P.; Uguen, D. Tetrahedron  Lett. 1993, 34, 4631-4634. 
79% yield, pale yellow oil. TLC Rf = 0.43 (50 % ethyl acetate/50 % hexanes ); 
1H NMR (300 
MHz, CDCl3) δ 7.28 (d, J = 8.7 Hz, 2 H), 6.91 (d, J = 8.7 Hz, 2 H), 4.48 (s, 2 H), 3.84 (s, 3 H), 
3.80 (t, J =5.5 Hz, 2 H), 3.67 (t, J =5.8 Hz, 2 H), 2.17 (bs, 1 H), 1.88 (q, J =5.7 Hz, 2 H). 
 
2-(4-Methoxybenzyloxy)ethanol 2.83. 
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Lit. Ref.: Kukase, K.; Tanaka, H.; Toriib, S.; Kusumoto, S. Tetrahedron  Lett. 1990, 31, 389-392. 
80% yield, yellow oil. TLC Rf = 0.32 (50 % ethyl acetate/50 % hexanes ); 
1H NMR (300 MHz, 
CDCl3) δ 7.30 (d, J = 7.8 Hz, 2 H), 6.92 (d, J = 11.6 Hz, 2 H), 4.53 (s, 2 H), 3.84 (s, 3 H), 3.78 
(t, J =4.7 Hz, 2 H), 3.61 (t, J =4.8 Hz, 2 H), 1.85 (bs, 1 H). 
 
4-[(4-Methoxyphenyl)methoxy]-2-butyn-1-ol 2.85. 
Lit. Ref.:  Hatakeyama, S.;  Yoshida, M.; Esumi, T.; Iwabuchi, Y.; Irie, H.; Kawamoto, T.; 
Yamada, H.; Nishizawa, M.  Tetrahedron  Lett. 1997, 38, 7887-7890. 
36% yield, yellow oil. TLC Rf = 0.52 (50 % ethyl acetate/50 % hexanes ); 
1H NMR (300 MHz, 
CDCl3) δ 7.30 (d, J = 6.6 Hz, 2 H), 6.91 (d, J = 11.6 Hz, 2 H), 4.56 (s, 2 H), 4.36 (t, J =1.8 Hz, 2 
H), 4.21 (t, J =2.1 Hz, 2 H), 3.84 (s, 3 H). 
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Appendix A. 1H AND 13C NMR SPECTRA SUPPLEMENT TO 
CHAPTER 2 
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Chapter 3: Modulation of SHIP for Therapeutic Purposes 
Abstract: 
The SH2-containing inositol 5’-phosphatase-1 (SHIP1) is an enzyme found in blood cells 
that is responsible for the hydrolysis of phosphatidylinositol-3,4,5-trisphosphate to 
phosphatidylinositol-4,5-bisphosphate.  This enzyme is part of a major cell signaling pathway 
(the PI3K pathway) that affects many important cellular functions such as proliferation, 
differentiation and adhesion.  SHIP1 inhibition has been found to increase blood cell production 
and slow the growth of blood cancer cells, and therefore SHIP1 inhibition with small molecules 
is being explored.  High throughput screening small molecule libraries identified several SHIP1 
inhibitors including 3α-aminocholestane (3AC).  3AC and certain other aminosteroids show 
selectivity as SHIP1 inhibitors and therefore may have therapeutic applications.  Further 
synthetic studies have been undertaken to determine which portions of the aminosteroid SHIP1 
inhibitor are important for biological activity.  In addition, modifications to the molecule which 
improve solubility and potency have also been pursued in order to facilitate the evaluation of 
these inhibitors in other biological settings.  In this chapter the syntheses of a number of 
aminosteroid derivatives and the evaluation of these compounds for their potential as SHIP1 
inhibitors is described. 
PI3K Signaling Pathway 
 When eukaryotic cells shuttle information about changes in the extracellular environment 
to the nucleus the signals must cross the cell membrane.  Enzymes on the interior of the cell 
membrane are integral to this process, as they initiate signaling cascades inside the cell that 
involves a complex system made up of both enzymes and second messengers such as 
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phosphatidylinositols.  Phosphatidylinositols play a prominent role in cell signaling.  These lipids 
are intercalated on the interior of the cell membrane and are used to assist in the transduction of 
signals across the plasma membrane from the external environment to the nucleus.  
Phosphatidylinositol signaling has a major influence in cell division and survival.1,2  This 
signaling also plays a role in cell differentiation and adhesion.1,2  
 One of the best known phosphatidylinositol signaling pathways is mediated by 
phosphatidylinositol-3-kinase, PI3K.  PI3K is responsible for phosphorylating 
phosphatidylinositol-4,5-bisphosphate, PI(4,5)P2, to form phosphatidylinositol-3,4,5-
trisphosphate, PI(3,4,5)P3 (Figure 3.1).  When activated, PI3K can rapidly synthesize PI(3,4,5)P3, 
which then activates a number of protein kinases resulting in an accelerating signal cascade 
through the cytoplasm to the nucleus.  Aberrant activation of PI3K is known to lead to cancer.3,4  
The phosphatase and tensin homolog protein, PTEN, also regulates this pathway.  The PTEN 
protein exerts its influence on the pathway by acting as a 3' inositol phosphatase, reversing the 
PI3K reaction by hydrolyzing PI(3,4,5)P3 back to PI(4,5)P2.  This function of PTEN is crucial, as 
PTEN knockout mice quickly develop terminal cancer.5,6  Other inositol phosphatases hydrolyze 
PI(3,4,5)P3 to PI(3,4)P2, a second, but distinct inositol bisphosphate.  In blood cells (and other 
cells related to the hematopoietic system), SH2-containing inositol 5’-phosphatase or SHIP1, is 
the inositol phosphatase that hydrolyzes PI(3,4,5)P3 to PI(3,4)P2.
2,7 Unlike PTEN, SHIP1 
knockout mice are viable and do not develop terminal cancer, although their immune system is 
modified.8,9  
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Figure 3.1: The PI3K Pathway 
 
 Many other signaling enzymes are involved in the transmission of the PI3K signal in 
order for it to reach the nucleus and exert its effects on cellular metabolism (Figure 3.2).  After 
PI(3,4,5)P3 is formed from PI3K, it binds with the protein kinase PDK1.  PDK1 then 
phosphorylates a second protein kinase AKT, which is activated and begins to phosphorylate a 
number of other protein kinases.10 Both PI(3,4,5)P3 and PI(3,4)P2 are required in the signaling 
pathway in order to fully activate AKT.11,12 Once activated, AKT controls the activation and 
inhibition of different functions relating to cellular survival and proliferation.  One kinase that 
AKT activates is mTOR, which controls regulatory cell growth pathways.  Inhibition at the start 
of the PI3K signaling pathway would cut off the branching of signals and may restore normal 
control of cell growth.  
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Figure 3.2: The PI3K Signaling Cascade13 
SHIP 
 SHIP plays a significant role in regulation of the PI3K signaling pathway.  By 
hydrolyzing PI(3,4,5)P3 to PI(3,4)P2, SHIP modulates the intensity of the signal and influences 
immune response and cellular division.14,15,16  There are three major paralogs of the SHIP 
enzyme:  SHIP1, SHIP2, and sSHIP.  The expression of SHIP1 occurs primarily in blood and 
bone marrow cells.  SHIP2 is expressed in a wide variety of cells throughout the rest of the body.  
The sSHIP enzyme is only expressed in stem cells.  A genetic study of SHIP1 determined that 
the enzyme plays a role in blood cell biology and immunology.14,15,16  Most importantly for this 
study, it was found that SHIP1 inhibition induces apoptosis in blood cancer cells.9 This 
implicates the development of SHIP1 inhibitors as a possible treatment for hematopoietic 
neoplasms. 
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 Attempts at crystallizing the whole SHIP enzyme have not been successful. Potter and 
coworkers were able to obtain a crystal structure of a portion of the SHIP2 enzyme containing 
the active site (Figure 3.3).17  The crystal structure was obtained when a biphenyl 2,3’,4,5’,6-
pentakisphosphate (BiPh(2,3’,4,5’,6)P5) synthetic ligand was bound to the catalytic site of the 
SHIP2 protein.  The biphenyl phosphate ligand bonds to the polar residues in the SHIP2 active 
site through hydrogen bond interactions in the binding pocket.  The 5' phosphate of 
BiPh(2,3',4,5',6)P5 mimics the 5'-phosphatase of PI(3,4,5)P3. This phosphate shows hydrogen 
bonds to Arg682, Tyr661 and Arg611. The hydrogen-bonding network forces the phosphate into 
a conformation where hydrolysis is facilitated.  Molecular modeling studies have implicated that 
a loop of the enzyme (the PI4M loop) near the active site folds over the (BiPh(2,3’,4,5’,6)P5) 
ligand and encloses it after it binds to SHIP2.  Analysis of SHIP2 binding to the small molecule 
is an excellent starting point for the development of small molecule inhibitors. 
Figure 3.3: Crystal Structure of SHIP2 
 
 
151 
 
Rationale for SHIP Antagonist or Agonist 
Control of PI(3,4,5)P3 production plays a critical role in signal transduction in the PI3K 
pathway. A possible way to govern PIP3 production is manipulation of the phosphatase enzyme 
SHIP.  Inhibition of the SHIP enzyme would stop PI(3,4,5)P3 from hydrolyzing to PI(3,4)P2 
while upregulating SHIP would convert all PI(3,4,5)P3 to PI(3,4)P2.  As both PI(3,4,5)P3 and 
PI(3,4)P2 are required for full activation of AKT, both inhibition and upregulation of SHIP may 
significantly affect the PI3K signaling pathway and could lead to blood cancer cell apoptosis 
depending on the molecular pathology of the neoplasm.  There are many possible uses for SHIP 
inhibitors including cancer, bone marrow transplantation, stem cell mobilization and 
transplantation, blood cell production, and obesity.  
Cancer 
 The PI3K-AKT-mTOR pathway is intimately involved in cell survival and therefore has 
become a focus for cancer treatment.18,19,20  SHIP1, SHIP2 and PTEN are the enzymes 
predominantly responsible for controlling the AKT-mTOR signaling, which influences the 
survival of cancer cells and tumors.  Since SHIP1 is primarily expressed in hematopoietic cells, 
SHIP1 inhibition may be used for therapeutic treatment regarding human blood cell cancers such 
as leukemia and multiple myeloma.8   
 Modulation of the other paralogs of SHIP may also be a useful strategy in the treatment 
of other types of cancer. SHIP2 overexpression has been implicated in the development of breast 
cancer, for example.7  SHIP2 causes an increase in EGF-induced signaling for various breast 
cancers which is atypical.  High levels of EGF-induced signaling can lead to an increase of 
cellular proliferation for the cancer cells.21  Various breast cancer cells lines overexpress SHIP2 
such as MDA-MB-231, SKBR-3, MDA-468, MDA-436, MCF-7 and ZR-75.  SHIP2 inhibition 
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for the MDA-MB-231 breast cancer cell line showed a dramatic decrease in cell proliferation 
demonstrating SHIP2’s potential for therapeutic cancer treatment of breast cancer.         
Bone Marrow Transplantation 
Small molecule SHIP1 inhibitors could also be effective at minimizing complications for 
bone marrow transplant recipients and the management of myelodysplastic syndromes.22,23 
SHIP1 inhibitors show potential for therapeutic possibilities in treating Graft vs Host disease 
(GvHD) caused by bone marrow transplants.24  Bone marrow transplants play a considerable role 
in organ transplants, as well as treatment of cancer and genetic disorders.23  However, these 
transplants are risky due to the occurrence of GvHD which can cause rejection of the transplant 
and ultimately death.  Experiments have shown that transplants of mismatched bone marrow 
grafts are well tolerated in SHIP1 knockout mice, as these mice possess a modified immune 
system which tolerates the grafts.  These mice do well with bone marrow transplants because 
they do not develop GvHD due to an increased expression of human T regulatory cell numbers.  
Even multiple kinds of mismatched bone marrow grafts are successful in SHIP1 knockout 
mice.25 SHIP1 inhibitors therefore have therapeutic potential in the area of organ transplants and 
engraftments.  
Stem Cell Mobilization and Transplantation 
 The proliferation of hematopoietic STEM cells (HSCs) is increased in SHIP1 knockout 
mice.26  Significantly more HSCs are found in the plasma of SHIP1 knockout mice instead of 
typically being found in the bone marrow.8  This suggests the use of a SHIP1 inhibitor could be 
used to mobilize STEM cells from the bone marrow to the bloodstream.  Once in the 
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bloodstream, the HSCs are much easier to harvest so they can then be used in HSC 
transplantation.  
Blood Cell Production 
SHIP1 inhibitors may be effective as a means to boost or protect blood cell production in 
cancer patients, helping prevent disease or infection as a result of neutropenia.22,23,26 SHIP1 
inhibition in the PI3K signaling pathway leads to an increase of PI(3,4,5)P3 which causes an 
increase in cell division specific to blood cells.  A small molecule SHIP1 inhibitor could be taken 
orally and used in cancer treatment where chemotherapy and radiation kill healthy hematopoietic 
cells.  Typically protein based growth factors are now used for this purpose, but because of their 
peptidic nature these drugs must be given intravenously.  In vivo studies with mice indicated an 
increase of blood cell production after the mice were administered a SHIP1 inhibitor.8  These in 
vivo mice studies demonstrate the therapeutic potential of SHIP1 inhibitors for blood cell 
production after chemotherapy or radiation poisoning.27,28   
Obesity  
 SHIP1 inhibition may be used to treat inflammatory pathways that can lead to obesity.  
By inhibiting SHIP1, expression of immunoregulatory cells is increased and can promote a lean-
body state.  Studies using mice that were fed a high fat diet showed a loss of body weight and fat 
content when treated with a SHIP1 inhibitor. Use of a SHIP1 inhibitor in adult aged mice 
diminished inflammation in the visceral adipose tissue (VAT) which can cause obesity.  These 
mice lost body fat and also gained lean muscle mass, despite being on a high calorie diet. Thus 
the use of a SHIP1 inhibitor could be a successful treatment for diet-associated obesity.29   
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Structure Activity Relationships 
High throughput screening with small molecule libraries discovered four types of SHIP 
inhibitors8, 35 have been discovered and they fall into the categories of aminosteroids (3.4), 
quinoline aminoalcohols (3.5), tryptamines (3.6) and thiophenes (3.7).  An example of each can 
be seen in Figure 3.4.  The aminosteroid 3AC (3.4) demonstrated selectivity for SHIP1 over 
other inositol phosphatases unlike 3.5 and 3.6, which are unselective SHIP1/SHIP2 inhibitors, 
and thiophenes (like 3.7) which are selective small molecule SHIP2 inhibitors.  The parent 
compound, 3AC (3.4), was unfortunately found to have very poor water solubility.   
Figure 3.4:  SHIP Inhibitors 
 
To address the poor water solubility, a number of analogs were synthesized.30  
Androsterone derivative 3.9, (Figure 3.5), is more soluble in water and has a higher potency as a 
SHIP1 inhibitor.  Compound 3.9 is not a selective SHIP1 inhibitor, however, as it shows equal 
inhibition of SHIP1 and SHIP2. Acylation or alkylation of the amine significantly reduced 
inhibitory activity.  Moreover, the inclusion of polar functional groups on the D ring was shown 
to decrease activity vs. SHIP1, like in the case of compound 3.13.   
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Figure 3.5:  Aminosteroid Analogues 
 
 From these structure activity studies, a general impression of the binding pocket for the 
aminosteroids can be proposed.  This model indicates that polar functionality is tolerated on the 
A ring while only hydrophobic groups are allowed on ring D (Figure 3.6).8 
Figure 3.6: Structure Activity Relationship of the Aminosteroid SHIP inhibitors 
 
The known crystal structure of SHIP2 led to our own molecular modeling of the SHIP1 
active site.17  Using the SHIP2 x-ray structure as a guide, a model of the SHIP1 active site was 
constructed in silico. Figure 3.7 shows this proposed model of the active site of SHIP1 and a 
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model with aminosteroid 3AC docked in the active site.  The model for SHIP1 is based on the 
crystal structure of the SHIP2 active site, but many of the residues near the active site have been 
changed as they are different than those found in SHIP2. The largest changes are seen in the 
PI4M loop region (Figure 3.7). In the model of 3.4 binding to SHIP1, the C17 sidechain on the D 
ring of the aminosteroid is in the PI4M loop region.  In the crystal structure for SHIP2 there is a 
threonine in the PI4M loop region, however, in SHIP1 there is a more lipophilic tyrosine.  This 
difference in amino acids may explain the selectivity of the inhibition for SHIP1 when we have a 
sidechain at C17.    
Figure 3.7: Proposed model of active site for SHIP1 
 
Figure 3.8 shows the % inhibition of aminosteroid inhibitors 3.4 (3AC), 3.9 (K185), and 
3.14 (K118) in the malachite green assay for phosphatase activity.  3AC showed selective 
inhibition for SHIP1, where as K185 and K118 showed inhibition for both SHIP1 and SHIP2.   
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Figure 3.8: SHIP Inhibition with Aminosteroids 
 
 
 Since androsterone derivative 3.9 (K185) showed improved solubility and an increased 
activity as a SHIP1 inhibitor from 3.4 (3AC), aminosteroids without or with a smaller carbon 
chain on the D ring were synthesized (Figure 3.9).  Based on the molecular modeling studies, it 
was thought that an aminosteroid with a smaller carbon chain on the D ring would maintain 
selectivity for SHIP1 while maintaining the improved water solubility.  The aminosteroid 3.9 
was not only synthesized on large scale but the β form of the aminosteroid (K118) was 
synthesized as well. In addition, two aminosteroid derivatives with alkenes on the D ring of the 
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steroid were synthesized. Finally, an aminosteroid with a methyl group on the D ring was 
prepared. 
Figure 3.9: SHIP1 Inhibitors and Potential Analogues 
 
Androsterone derivatives  
For the synthesis of analogue 3.9, a supply of steroid 3.19 was needed as the starting 
material.  Reduction of androsterone 3.18 through a Yamamura-Clemmensen reduction was 
explored for this purpose as an alternative to the Wolff-Kishner (Figure 3.10), which was 
providing irreproducible yields.31   
Figure 3.10: Clemmensen Reduction of Trans-Androsterone 
 
The Clemmensen reduction was thought to be a more attractive methodology because the 
reaction is faster and proceeds at a lower temperature than the Wolff-Kishner reduction.31  The 
reaction was optimized by varying the amounts of zinc metal and TMSCl used, as well as the 
reaction time and concentration. Eventually an 85% yield of the desired product was obtained. 
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However, when the reaction scale was increased to two grams, only 56% yield was obtained 
(Table 3.1).  Also, 1H NMR spectra showed an unidentified minor impurity in the product that 
could not be removed.  This impurity did not appear in the product when a Wolff-Kishner 
reduction was used.   
Table 3.1: Clemmensen Reduction of Trans-Androsterone 
 
Entry 
mmol 
Zn/TMSCl 
Equivalents 
Zn/ TMSCl 
Concentration 
(M) 
Time 
Percent 
yield 
1 20/20 100/100 0.01 1 hour 81 
2 20/20 100/100 0.01 24 hours 49 
3 5/5 25/25 0.01 1 hour 60 
4 20/20 100/100 0.04 1 hour 78 
5 2/2 10/10 0.1 1 hour 52 
6 4/4 20/20 0.1 1 hour 42 
7 4/4 20/20 0.04 1 hour 54 
8 8/8 40/40 0.04 1 hour 76 
9 20/5 100/25 0.04 5 hours 85 
10 20/5 100/25 0.04 1 hour 80 
11 723/181 100/25 0.04 1 hour 56a 
a 2 gram scale (7.23 mmol)         
To circumvent the Clemmensen and Wolff-Kishner reactions, hydrazone 3.20 was 
prepared (Table 3.2).32  This hydrazone may then be reduced with a number of reducing agents. 
Though the proposed synthetic route will introduce more steps to the original synthesis, 
producing steroid 3.19 under mild conditions in high yield on large scale was key to our efforts.  
Ketone 3.18 was converted to the hydrazone 3.20 by refluxing with hydrazine in ethanol.  Crude 
hydrazone 3.20 was then exposed to different reduction conditions (Table 3.2), including 
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exposure to either potassium tert-butoxide or potassium bis(trimethylsilyl) amide.  The reaction 
was also performed at room temperature in DMSO or refluxed in toluene.  However, none of the 
reaction conditions gave a high yield of the product. 
Table 3.2: Reduction of Hydrazone 3.20 
 
Entry Base Solvent Temperature Time % Yield 
1 KOC(CH3)3 Toluene 110
oC 5 hours -- 
2 KOC(CH3)3 DMSO rt 16 hours -- 
3 KOC(CH3)3 DMSO rt 8 hours 9 % 
4 KOC(CH3)3 DMSO rt 24 hours -- 
5 KHMDS DMSO rt 22 hours 6% 
6 KOC(CH3)3 Toluene 110
oC 24 hours 2% 
 
 Because of the low yield observed in the preparation of 3.19 through hydrazone removal 
of 3.20, the Wolff-Kishner reaction was re-explored. A modified Wolff-Kishner reaction was 
employed for the ketone reduction of the androsterone where diethylene glycol was used to 
conduct the reaction in a much higher temperature.33 In addition, a brine solution was used in the 
workup and methyl tert-butyl ether was used in the extraction in place of HCl and DCM, which 
facilitated the isolation of the reaction product.33  The extraction with brine and MTBE was very 
clean and contained no precipitates.  When DCM and HCl were employed the extraction was 
messy and contained insoluble salts making the extraction difficult.  The cleaner extraction 
conditions with MTBE and brine allowed for a higher yield of product.  These conditions 
allowed for the large scale reduction of ketone 3.18 with a 69% yield. Later it was found that 
water generated by the formation of the hydrazide was lowering the boiling point of the reaction 
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mixture in the Wolff-Kishner reaction, which was the cause for the more moderate yields on 
large scale. Simply distilling off approximately half the diethylene glycol removed the water and 
led to consistently high yields of the desired product. 
 A large scale synthesis of  aminosteroid 3.9 (K185) was needed by our collaborators for 
biological testing.  Using the modified Wolff-Kishner conditions, androsterone was reduced to 
alcohol 3.19.  A Mitsunobu reaction was performed on alcohol 3.19 to convert it to phthalimide 
3.21.  Phthalimide was used for the installation of the nitrogen because of its easy reduction to an 
amine.  The phthalimide group was then removed with hydrazine to give amine 3.22.  HCl (g) 
was used to form the aminosteroid salt 3.9 (Figure 3.11).   
Figure 3.11: Synthesis of Aminosteroid K185 
 
 The aminosteroid K118 (3.14) was synthesized on large scale, as this molecule also 
shows significant activity as a SHIP inhibitor and good water solubility properties. Alcohol 3.19 
was subjected to a Mitsunobu reaction with iodomethane to provide iodide 3.23.  Iodide 3.23 was 
displaced with sodium azide to give β azide 3.24.  Initially, a lithium aluminum hydride 
reduction was used to reduce the azide 3.24 to amine 3.25.  However, the aluminum salt 
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impurities from the hydride reduction proved difficult to remove.  Instead, Staudinger conditions 
were used to reduce azide 3.24 to amine 3.25.  Amine salt 3.14 was then formed utilizing the 
reaction of hydrogen chloride (HCl) gas with amine 3.25 (Figure 3.12). 
Figure 3.12: Synthesis of Aminosteroid K118 
 
 For the synthesis of aminosteroid K179 (3.15), trans-androsterone was used as the 
starting material.  The ketone on the D ring first needed to be converted to an internal alkene.  In 
order to accomplish this transformation, a Shapiro reaction was investigated.  Androsterone 3.18 
was initially converted to tosylhydrazone 3.26.34  A Shapiro reaction using methyl lithium was 
used to transform the tosylhydrazone to alkene 3.27.34  Mitsunobu reaction with DPPA was then 
used to introduce the azide in steroid 3.28.  Azide 3.28 was reduced to amine 3.29 using lithium 
aluminum hydride, and aminosteroid salt 3.15 (K179) was formed using a solution of HCl in 
ether and amine 3.29 (Figure 3.13).    
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Figure 3.13: Synthesis of Aminosteroid K179 
 
In addition, the synthesis of aminosteroid 3.16 was performed in a similar manner to the 
synthesis of alkene 3.15.  A Wittig reaction was performed on trans-androsterone 3.18 which 
allowed for the installation of external alkene on the D ring of the steroid.  Initially, sodium 
hydride was used for the Wittig reaction but no product was observed, perhaps because the 
sodium hydride had degraded over time.  The use of n-butyl lithium instead of sodium hydride 
gave a product yield of 79% for this Wittig reaction.  The alcohol 3.30 was then converted to 
phthalimide 3.31 through a Mitsunobu reaction.  Aminosteroid salt 3.16 was made from alkene 
3.32 using HCl in methanol/ethyl acetate (which was conveniently formed by the addition of 
acetyl chloride to methanol, followed by the addition of ethyl acetate) to provide the amine salt.   
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Figure 3.14: Synthesis of Alkene 3.16 
 
The synthesis of amine hydrochloride salt 3.17 was then attempted starting with the 
reduction of alkene 3.30.  The reduction of the alkene on the D ring of 3.30 was performed using 
a palladium catalyzed hydrogenation.  This reaction allowed for the installation of a methyl 
group on the D ring of the steroid nucleus.  The stereochemistry of the methyl group is assumed 
to be controlled by the nearby axial methyl group, which precludes axial attack and leads 
selectively to the product shown. The alcohol 3.33 was then subjected to a Mitsunobu reaction to 
provide phthalimide 3.34.  Removal of the phthalimide group with hydrazine then gave amine 
3.35.  Aminosteroid salt 3.17 was formed utilizing HCl (g) and amine 3.35 (Figure 3.15). 
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Figure 3.15: Synthesis of Potential SHIP Inhibitor 3.17 
 
 After the proposed SHIP inhibitors were synthesized, they were tested for inhibition of 
both SHIP1 and SHIP2 utilizing the malachite green assay.8  The results are shown in Figure 
3.16.  K185 (3.9) and K118 (3.14) were also included for comparison since they show inhibition 
of SHIP1 and SHIP2. However, K185 demonstrated higher toxicity in mice studies than K118.  
An exploration of β-isomers may lead to a less toxic SHIP inhibitor.  K179 (3.15) was active for 
inhibition of both SHIP1 and SHIP2.  The biological activity of aminosteroids 3.16 and 3.17 is 
still being explored.  These studies demonstrate that a longer alkyl C-17 chain on the D ring of 
the steroid maybe necessary for selective SHIP1 inhibition. Additionally a C16-C17 alkene is 
tolerated in the binding pocket, opening the way for the preparation of other analogs with 
substitution at C17 and unsaturation at C16-C17. 
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Figure 3.16: % SHIP Inhibition of Aminosteroids with K179 
 
 
Conclusions 
 A number of aminosteroid derivatives were synthesized and tested for their ability to 
inhibit SHIP.  Removal of the C-17 carbon chain on the D-ring of the steroid was explored.  The 
steroids 3.9 (K185), 3.14 (K118), and 3.15 (K179) showed high potency but lost selectivity for 
SHIP1 inhibition.  Molecular modeling predicted a need for a long carbon chain at C-17 for 
selective binding to SHIP1 over SHIP2.  Aminosteroids with alkenes on the C-17 carbon were 
synthesized and showed activity as SHIP inhibitors.  Installing alkenes allows for 
functionalization of the D ring of the steroid, with the goal being installation of the shortest 
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carbon chain that maintains SHIP1 selectivity but also provides a compound with good water 
solubility so it may be used in animal studies.  Further studies of the aminosteroid with smaller 
carbon chains on the D-ring are now being conducted.  These aminosteroids show activity for the 
treatment of blood cancer cells and may have uses in the treatment of obesity.   
Experimental Procedures 
General Information. All anhydrous reactions were run under a positive pressure of argon or 
nitrogen. All syringes, needles, and reaction flasks required for anhydrous reactions were dried in 
an oven and cooled under an N2 atmosphere or in a desiccator. DCM and THF were dried by 
passage through an alumina column. Triethylamine was distilled from CaH2. All other reagents 
and solvents were purchased from commercial sources and used without further purification. 
Analysis and Purification. Analytical thin layer chromatography (TLC) was performed on 
precoated glass backed plates (silica gel 60 F254; 0.25 mm thickness). The TLC plates were 
visualized by UV illumination and by staining. Solvents for chromatography are listed as 
volume:volume ratios. Flash column chromatography was carried out on silica gel (40-63 μm). 
Melting points were recorded using an electrothermal melting point apparatus and are uncorrected. 
Elemental analyses were performed on an elemental analyzer with a thermal conductivity detector 
and 2 meter GC column maintained at 50 °C. 
Identity. Proton (1H NMR) and carbon (13C NMR) nuclear magnetic resonance spectra were 
recorded at 300 or 400 MHz and 75 or 100 MHz respectively. The chemical shifts are given in 
parts per million (ppm) on the delta (δ) scale. Coupling constants are reported in hertz (Hz). The 
spectra were recorded in solutions of deuterated chloroform (CDCl3), with residual chloroform ( 
7.26 ppm for 1H NMR, δ 77.23 ppm for 13C NMR) or tetramethylsilane ( 0.00 for 1H NMR,  
0.00 for 13C NMR) as the internal reference. Data are reported as follows: (s = singlet; d = doublet; 
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t = triplet; q = quartet; p = pentet; sep = septet; dd = doublet of doublets; dt = doublet of triplets; 
td = triplet of doublets; tt = triplet of triplets; qd = quartet of doublets; ddd = doublet of doublet of 
doublets; br s = broad singlet). Where applicable, the number of protons attached to the 
corresponding carbon atom was determined by DEPT 135 NMR. Infrared (IR) spectra were 
obtained as thin films on NaCl plates by dissolving the compound in CH2Cl2 followed by 
evaporation or as KBr pellets. 
 
 
5–Androstan–3–ol (3.19) 
Lit. Ref.: Norden, S.; Bender, M.; Rullkötter, J.; Christoffers, J.  Eur. J. Org. Chem. 2011. 4543–
4550.  
In a flame–dried flask, potassium hydroxide (4.764 g, 84.9 mmol) was dissolved in diethylene 
glycol (41 mL) by heating. The solution was cooled to rt before adding trans–androsterone (6 g, 
20.7 mmol) and hydrazine hydrate (3 mL, 62.1 mmol). The solution was heated to reflux. After 24 
h, the solution was cooled to rt and the reaction mixture was quenched by adding brine (600 mL). 
The mixture was extracted with MTBE (3 x 200 mL). The organic layers were collected, combined, 
dried over magnesium sulfate, filtered, and concd under reduced pressure. Purification was done 
with column chromatography (20% ethyl acetate/hexanes) to give 3.19 as a white solid (3.946 g, 
69%).  3.19. mp = 149.3–150.7 oC (DCM) (Lit: 151–152 oC); TLC Rf = 0.33 (ethyl acetate:hexane, 
1:4); IR (KBr) 3350, 2930, 2845, 1447, 1377, 1133 cm–1; 1H NMR (300 MHz, CDCl3)  3.58 
(hept, J = 4.9 Hz, 1H), 1.76–1.82 (m, 1H), 1.70–1.75 (m, 2H), 1.65–1.69 (m, 2H), 1.61–1.63 (m, 
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1H), 1.57–1.60 (m, 1H), 1.52–1.57 (m, 2H), 1.47–1.50 (m, 1H), 1.40–1.45 (m, 1H), 1.33–1.39 (m, 
1H), 1.29–1.30 (m, 1H), 1.22–1.28 (m, 4H), 1.04–1.17 (m, 4H), 0.9–1.02 (m, 1H), 0.85–0.93 (m, 
2H), 0.80 (s, 3H), 0.68 (s, 3H) 0.60–0.65 (m, 1H); 13C NMR (75 MHz, CDCl3)  71.6, 54.8, 54.7, 
45.1, 41.0, 40.6, 39.1, 38.4, 37.3, 36.1, 35.8, 32.7, 31.7, 29.0, 25.7, 21.5, 20.7, 17.7, 12.6. 
 
 
3–Phthalimido–5–androstane (3.21) 
In a 100 mL round bottom flask, 5–androstan–3–ol 3.19 (1.0 g, 3.62 mmol) was dissolved in 
dry THF (36 mL). Triphenylphosphine (1.138 g, 4.34 mmol) was added into the solution 
followed by diisopropyl azodicarboxylate (DIAD) (0.86 mL, 4.34 mmol). The resulting yellow 
solution was stirred continuously at rt for 10 min before adding phthalimide (639 mg, 4.34 
mmol). The solution was stirred continuously at rt. After 24 h, the reaction mixture was concd 
and the residue was purified with column chromatography (hexanes) to give 3.21 as a white solid 
(0.927 g, 63%).  3.21.  TLC Rf = 0.39 (10% ethyl acetate/hexane); 
1H NMR (300 MHz, CDCl3) δ 
7.78-7.83 (m, 2H), 7.67-7.74 (m, 2H), 4.49-4.51 (m, 1H), 0.81-2.12 (m, 33H), 0.73 (s, 3H). 
 
3–amino–5–androstane (3.22) 
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Lit. Ref.: Cowell, D. B.; Davis, A. K.; Mathieson, D. W.; Nicklin, P. D. J. Chem. Soc., Perkin 
Trans. 1. 1974, 1505-1513. 
In a 250 mL round bottom flask 3–Phthalimido–5–androstane 3.21 (1.413 g, 3.48 mmol) was 
suspended in 70 ml MeOH.  Hydrazine (13 mL, 271 mmol) was added and the reaction refluxed 
for one hour.  The solvent was evaporated and the residue was dissolved in DCM (20 mL).  The 
solution was extracted with NaOH (20 mL, 1M) 5 times.  The organic layers were collected, 
combined, dried with sodium sulfate, filtered and concentrated.  Purification was done with 
column chromatography (90:9:1 DCM:MeOH:NH4OH) to give 3.22 as a clear oil (724 mg, 
75%). 3.22. IR (KBr) 2926, 2855, 1472, 1378, 1124, 753 cm–1; 1H NMR (300 MHz, CDCl3)  
3.18 (bs, 1H), 1.71–1.73 (m, 2H), 1.65–1.69 (m, 3H), 1.61–1.63 (m, 1H), 1.59–1.60 (m, 1H), 
1.55–1.57 (m, 2H), 1.50–1.53 (m, 1H), 1.40–1.45 (m, 3H), 1.30–1.32 (m, 1H), 1.23–1.29 (m, 
3H), 1.18–1.21 (m, 3H), 1.14–1.18 (m, 2H), 1.07–1.10 (m, 2H), 0.89–1.99 (m, 2H), 0.78 (s, 3H), 
0.69 (s, 3H). 
 
 
3–Amino–5–androstane hydrochloride (3.9) 
The –amine 3.22 (1.135 g, 4.12 mmol) was dissolved in diethyl ether (5 mL).  Hydrogen chloride 
(g), resulting from sulfuric acid being added to sodium chloride, was bubbled into the diethyl ether 
which resulted in precipitate formation. The suspension was filtered.  The precipitate was collected 
and dried under vacuum to afford amine salt 3.9 (1.139 g, 89%) as a white solid. 3.9. mp = 252.2 
oC (diethyl ether) (dec.); IR (KBr) 3320, 2945, 1619, 1495, 1443, 1379 cm–1; 1H NMR (300 MHz, 
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CDCl3)  8.45 (bs, 3H), 3.60 (bs, 1H), 1.84 (bs, 2H), 1.62–1.69 (m, 8H), 1.51–1.58 (m, 4H), 1.37–
1.44 (m, 1H), 1.23–1.29 (m, 2H), 1.09–1.20 (m, 4H), 0.92–1.07 (m, 3H), 0.79 (s, 3H), 0.69 (s, 
3H); ); 13C NMR (75 MHz, CD3OD)  54.2, 53.3, 48.0, 41.0, 40.6, 38.9, 38.8, 36.3, 36.0, 32.3, 
31.6, 28.6, 25.6, 25.0, 20.9, 20.7, 17.8, 11.6. Anal calcd for C19H34ClN: C, 73.16; H, 10.99; N, 
4.49. Found: C, 73.56; H, 11.19; N, 4.50. 
 
 
(3R,5S,8S,9S,10S,13S,14S)–3–iodo–10,13–dimethylhexadecahydro–1H–
cyclopenta[a]phenanthrene (3.23) 
In a flame dried round bottom flask, –alcohol 3.19 (1.00 g, 3.62 mmol) and triphenylphosphine 
(1.138 g, 4.34 mmol) were dissolved in dry benzene (20 mL). A solution of DIAD (0.86 mL, 4.34 
mmol) in dry benzene (8 mL) was added dropwise over several minutes followed by a solution of 
iodomethane (0.27 mL, 4.34 mmol) in dry benzene (8 mL). The resulting milky yellow solution 
was stirred continuously at rt. After approximately 24 h, the reaction mixture was concd and the 
residue was purified through flash column chromatography eluting with hexane which afforded 
3.23 (1.194 g, 85%) as a white solid.  3.23. 1H NMR (300 MHz, CDCl3)  4.94 (quint, J = 2.6 Hz, 
1H), 1.91 (pt, J = 15.4, 3.3 Hz, 1H), 1.70–1.76 (m, 1H), 1.66–1.69 (m, 2H), 1.59–1.64 (m, 3H), 
1.56–1.58 (m, 1H), 1.52–1.54 (m, 1H), 1.49 (t, J = 3.3 Hz, 1H), 1.45 (t, J = 2.2 Hz, 1H), 1.39–1.43 
(m, 1H), 1.30–1.36 (m, 1H), 1.28 (d, J = 4.0 Hz, 1H), 1.22–1.26 (m, 2H), 1.18–1.21 (m, 1H), 1.13–
1.17 (m, 2H), 1.07–1.11 (m, 1H), 0.97–1.04 (m, 1H), 0.89–0.95 (m, 1H), 0.83–0.87 (m, 1H), 0.79 
(s, 3H), 0.69 (s, 3H).  
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(3S,5S,8S,9S,10S,13S,14S)–3–azido–10,13–dimethylhexadecahydro–1H–
cyclopenta[a]phenanthrene (3.24) 
In a flame dried–round bottom flask, iodide 3.23 (1.483 g, 3.84 mmol) and sodium azide (2.496 g, 
38.4 mmol) were suspended in dry DMF (20 mL). The suspension was heated to 80 oC. After 5 
hours, the solution was cooled at rt before quenching the reaction by adding water (200 mL). The 
quenched reaction mixture was extracted with diethyl ether (3 x 200 mL). The organic layers were 
collected, combined, dried over magnesium sulfate, filtered, and concd under reduced pressure. 
Purification using flash column chromatography with hexane was done to afford azide 3.24 (0.859 
g, 74%) as white solid.  3.24. TLC Rf = 0.38 (hexanes);  1H NMR (300 MHz, CDCl3)  3.25 (dt, J 
= 12.9, 4.5 Hz, 1H), 1.78–1.86 (m, 1H), 1.72–1.76 (m, 1H), 1.64–1.71 (m, 2H), 1.58–1.63 (m, 2H), 
1.52–1.57 (m, 2H), 1.48–1.51 (m, 1H), 1.44–1.47 (m, 1H), 1.40–1.43 (m, 1H), 1.33–1.39 (m, 1H), 
1.20–1.31 (m, 4H), 1.02–1.19 (m, 4H), 0.83– 0.99 (m, 3H), 0.80 (s, 3H), 0.68 (s, 3H), 0.61–0.70 
(m, 1H). 
 
3β–Amino–5–androstane (3.25) 
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Lit. Ref.: Cowell, D. B.; Davis, A. K.; Mathieson, D. W.; Nicklin, P. D. J. Chem. Soc., Perkin 
Trans. 1. 1974, 1505-1513. 
In a flame dried flask, azide 3.24 (1.694 g, 5.62 mmol) and triphenylphosphine (2.938 g, 11.2 
mmol) was dissolved in dry THF (26 mL). The solution was stirred continuously at rt. After 
approximately 2 hours, water (7 mL) was added and the solution was heated to reflux overnight. 
The solution was cooled at rt. The organic layer was collected, dried over sodium sulfate, and 
concd under reduced pressure. Purification was done with column chromatography (90:9:1 DCM: 
MeOH: NH4OH) to give 3.25 as a clear oil (1.456 g, 94%). 3.25.  
1H NMR (300 MHz, CDCl3)  
2.59-2.74 (m, 1H), 1.99 (bs, 2H), 0.61-1.73 (m, 35H).   
 
3β–Amino–5–androstane hydrochloride (3.14) 
Lit. Ref.: Cowell, D. B.; Davis, A. K.; Mathieson, D. W.; Nicklin, P. D. J. Chem. Soc., Perkin 
Trans. 1. 1974, 1505-1513. 
The β–amine 3.25 (1.456 g, 5.29 mmol) was dissolved in diethyl ether (10 mL).  Hydrogen chloride 
(g), resulting from sulfuric acid being added to sodium chloride, was bubbled into the diethyl ether 
solution which resulted in precipitate formation. The suspension was filtered.  The precipitate was 
collected and dried under vacuum to afford amine salt 3.14 (1.589 g, 96%) as a white solid. 3.14. 
mp = 276.2 oC (diethyl ether) (dec.); IR (KBr) 3449, 2928, 2361, 1984, 1451, 1377 cm–1; 
1H NMR 
(300 MHz, CDCl3)  8.29 (bs, 3H), 3.13 (bs, 1H), 1.99 (app d, 1H), 1.55–1.580 (m, 10H), 1.38–
1.48 (m, 2H), 1.23–1.35 (m, 4H), 1.06–1.19 (m, 4H), 0.89– 1.02 (m, 3H), 0.84 (s, 3H), 0.68 (s, 
3H); 13C NMR (75 MHz, CDCl3)  54.7, 54.5, 51.5, 45.3, 41.0, 40.6, 39.0, 36.9, 35.9, 35.7, 33.3, 
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32.4, 28.5, 27.1, 25.7, 21.3, 20.7, 17.8, 12.5. Anal calcd for C19H34ClN: C, 73.16; H, 10.99; N, 
4.49. Found: C, 72.96; H, 10.80; N, 4.31. 
 
 
(3S,5S,8S,9S,10S,13S,14S)-10,13-Dimethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-
3-ol (3.19). 
Lit. Ref.:  Xu, S.; Toyama, T.; Nakamura, J.; Arimoto, H.  Tetrahedron Letters. 2010, 51, 4534-
4537. 
In a round bottom flask, trans-androsterone (58 mg, 0.20 mmol) was dissolved in 3:1 
methanol/dichloromethane (5 mL) and cooled to 0oC.  Zinc (1.308 g, 20 mmol) was added to the 
solution followed by chlorotrimethylsilane (0.635 mL, 5 mmol) dropwise at 0oC.  The reaction 
was stirred for 1 hour.  Solid sodium bicarbonate (2.016 g, 24 mmol) was added to quench the 
reaction. The mixture was filtered and the filtrate was concentrated.  The residue was diluted 
with saturated aqueous ammonium chloride and extracted with dichloromethane.  The organic 
layer was dried using sodium sulfate, filtered and concentrated. Purification was done with flash 
column chromatography (25% ethyl acetate/hexanes) to give solid 3.19 (44 mg, 80%). 3.19.  mp 
= 149-150oC (CDCl3); TLC Rf = 0.33 (25% ethyl acetate/hexanes);  IR (neat) 3349, 2930, 2844 
cm-1; 1H NMR (300 MHz, CDCl3)  δ 3.59 (m, 1H), 0.59-1.82 (m, 34H). 
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N'-((3S,5S,8R,9S,10S,13S,14S)-3-hydroxy-10,13-dimethyl-tetradecahydro-2H-
cyclopenta[a]phenanthren-17(14H)-ylidene)-4-methylbenzenesulfonohydrazide  
Lit. Ref.: Anderson, A.; Boyd, A.C.; Clark, J.K.; Fielding, L.; Gemmell, D.K.; Hamilton, N.M; 
Maidment, M.S.; May, V.; McGuire, R.; McPhail, P.; Sansbury, F.H.; Sundaram, H.; Taylor, R.    
J. Med. Chem. 2000, 43, 4118-4125. 
In a 50 mL round bottom flask, trans-androsterone (2.00 g, 6.89 mmol), p-toluene sulfonyl 
hydrazide (1.42 g, 7.62 mmol), and p-toluene sulfonic acid monohydrate (20 mg, 0.1 mmol) 
were dissolved in ethanol (10 mL).  The reaction refluxed overnight.  The next day additional p-
toluene sulfonyl hydrazide (700 mg) and p-toluene sulfonic acid monohydrate (20 mg) were 
added.  The reaction refluxed for another 5 hours.  The solvent was evaporated under reduced 
pressure.  Purification was done with flash column chromatography (1:1 ethyl acetate/hexanes) 
to give KTH-1-123 as white solid (4.006 g, 63%). mp = 161-186oC (1:1 ethyl acetate/hexanes);  
TLC Rf = 0.08 (25% ethyl acetate/hexanes); IR (neat) 3400, 3200, 2926, 1597, 1333, 1165 cm
-1; 
1H NMR (300 MHz, CDCl3) δ 7.82 (d, J = 8.4 Hz, 2H), 7.29 (d, J = 7.8 Hz, 2H), 3.50-3.58 (m, 
1H), 2.42 (s, 3H), 0.77-2.22 (m, 28H). 
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(3S,5S,8R,9S,10S,13R,14S)-10,13-dimethyl-2,3,4,5,6,7,8,9,10,11,12,13,14,15-tetradecahydro-
1H-cyclopenta[a]phenanthren-3-ol (3.27) 
Lit. Ref.:  Anderson, A.; Boyd, A.C.; Clark, J.K.; Fielding, L.; Gemmell, D.K.; Hamilton, N.M; 
Maidment, M.S.; May, V.; McGuire, R.; McPhail, P.; Sansbury, F.H.; Sundaram, H.; Taylor, R.    
J. Med. Chem. 2000, 43, 4118-4125. 
In a flame dried 50 mL round bottom flask, 3.26 was dissolved in dry THF (11 mL) and cooled 
to 0oC.  Methyl lithium (3 M in diethoxymethane, 2.4 mL, 7.19 mmol) was added dropwise over 
5 minutes.  A precipitate formed and redissolved as methyl lithium addition continued.  The red 
solution was stirred at room temperature for 24 hours.  Methyl lithium (3 M in diethoxymethane, 
1.2 mL, 3.6 mmol) was added to the flask and the reaction stirred for 6 hours.  The reaction was 
quenched with slow addition of water, then diethyl ether was added.  The mixture was acidified 
with 2 M hydrochloric acid.  The organic layer was separated, washed with water twice then 
brine once, dried with sodium sulfate and concentrated.  Purification was done using column 
chromatography (15% ethyl acetate/hexanes) to give 3.27 as a white solid (248 mg, 41%). 3.27. 
mp = 114-118oC (15% ethyl acetate/hexanes);  TLC Rf = 0.40 (25% ethyl acetate/hexanes); IR 
(neat) 3246, 3044, 2934, 2846, 1449, 1042 cm-1; 1H NMR (300 MHz, CDCl3) δ 5.83 (d, J = 9.3 
Hz, 1H), 5.66-5.70 (m, 1H), 3.53-3.64 (m, 1H), 0.75-2.13 (m, 28H). 
 
 
(3R,5S,8R,9S,10S,13R,14S)-3-azido-10,13-dimethyl-2,3,4,5,6,7,8,9,10,11,12,13,14,15-
tetradecahydro-1H-cyclopenta[a]phenanthrene (3.28) 
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Lit. Ref.: Amiranashvili, L. Sh.; Sladkov, V. I.; Levina, I. I.; Men'shova, N. I.; Suvorov, N. 
N.  Journal of Organic Chemistry USSR. 1990, 26,  # 9.1  p. 1629-1632.  
In a 50 mL round bottom flask, alcohol 3.27 (0.24 g, 0.875 mmol) was dissolved in dry THF (9 
mL). Triphenylphosphine (0.23 g, 0.875 mmol) was added into the solution followed by 
diisopropryl azodicarboxylate (DIAD) (0.17 mL, 0.875 mmol). The resulting yellow solution 
was stirred continuously at rt for 10 min before adding diphenylphosphoryl azide (0.23 mL, 1.05 
mmol). The solution was stirred continuously at rt. After 24 h, the reaction mixture was concd 
and the residue was purified with column chromatography to give 3.28 as a white solid (0.193 g, 
74%).%). 3.28. TLC Rf = 0.33 (Hexanes); 
1H NMR (300 MHz, CDCl3) δ 5.81-5.83 (m, 1H), 
5.69-5.70 (m, 1H), 3.87-3.89 (m, 1H), 0.75- 1.89 (m, 28H). 
 
(3R,5S,8R,9S,10S,13R,14S)-10,13-dimethyl-2,3,4,5,6,7,8,9,10,11,12,13,14,15-
tetradecahydro-1H-cyclopenta[a]phenanthren-3-amine (3.29) 
In a flame dried round bottom flask, LAH (0.085 g, 2.13 mmol, 95%) was suspended in dry THF 
(2.5 mL). The suspension was cooled at 0 oC using ice/water cold bath before adding the solution 
of –azide 3.28 (0.193 g, 0.645 mmol) in dry THF (2.5 mL). The solution was warmed to rt and 
then refluxed for 5 hours. The reaction was then cooled to rt before diluting the solution with 
THF (5 mL). The diluted reaction mixture was cooled at 0 oC and quenched using a Fieser 
method.5 The reaction mixture was stirred continuously until it turned into a milky white 
suspension. The suspension was then filtered through celite and washed with THF. The filtrate 
was dried over sodium sulfate and concd under reduced pressure.  Purification was done with 
column chromatography (90:9:1 DCM: MeOH: NH4OH) to afford –amine 3.29 (0.113 g, 64%).  
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3.29. TLC Rf = 0.23 (90:9:1 DCM: MeOH: NH4OH); 
1H NMR (300 MHz, CDCl3) δ 5.79-5.82 
(m, 1H), 5.67-5.68 (m, 1H), 3.16 (s, 1H), 0.73-1.87 (m, 28H). 
 
 
(3R,5S,8R,9S,10S,13R,14S)-10,13-dimethyl-2,3,4,5,6,7,8,9,10,11,12,13,14,15-
tetradecahydro-1H-cyclopenta[a]phenanthren-3-amine hydrochloride (3.15) 
The –amine 3.29 (0.100 g, 0.366 mmol) was dissolved in diethyl ether (5 mL). A solution of 
hydrogen chloride in diethyl ether (0.37 mL, 2 M) was added dropwise which resulted in 
precipitate formation. The suspension was filtered and the precipitate was collected, washed with 
diethyl ether, and dried under vacuum to afford amine salt 3.15 (0.106 g, 94%) as a white solid. 
1H NMR (300 MHz, DMSO-d6) δ 7.98 (bs, 3H), 5.84 (bs, 1H), 5.68 (bs, 1H), 3.34 (bs, 1H), 0.72-
2.03 (m, 34H).  Anal calcd for C19H32ClN: C, 73.63; H, 10.41; N, 4.52. Found: C, 73.31; H, 10.15; 
N, 4.73.  
 
 
(3S,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-17-methylene-hexadecahydro-1H-
cyclopenta[a]phenanthren-3-ol (3.30) 
Lit. Ref.: Norden, S.; Bender, M.; Rullkötter, J.; Christoffers, J.  Eur. J. Org. Chem. 2011. 4543–
4550.  
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 [Ph3PMe]Br (6.144 g, 17.2 mmol) was suspended in dry THF (24 mL).  The suspension was 
cooled to 0oC and n-butyl lithium was added slowly (6.88 mL, 17.2 mmol, 2.5 M in hexanes).  A 
solution of 3.18 (1.0 g, 3.44 mmol) in dry THF (33 mL) was added dropwise, and the resulting 
mixture was stirred at reflux for 20 hours. After cooling to room temperature, some water was 
added dropwise, and then the mixture was diluted with water (200 mL) and diethyl ether (200 
mL). The layers were separated, and the aqueous layer was extracted with diethyl ether (2 X 150 
mL). The combined organic layers were dried MgSO4, filtered, and concentrated.  Purification 
was done with column chromatography (1:1 Et2O: hexanes) to yield 3.30 (0.782 g, 79 as a white 
solid.  3.30.  TLC Rf = 0.57 (2:1 Et2O:hexanes); 
1H NMR (300 MHz, CDCl3) δ 4.61 (s, 1H), 4.59 
(s, 1H), 3.49-3.67 (m, 1H), 2.50-2.63 (m, 1H), 2.12-2.31 (m, 1H), 0.65-1.82 (m, 30H). 
 
2-((3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-17-methylene-hexadecahydro-1H-
cyclopenta[a]phenanthren-3-yl)isoindoline-1,3-dione (3.31) 
In a 100 mL round bottom flask, 5–androstan–3–ol 3.30 (0.782 g, 2.71 mmol) was dissolved 
in dry THF (27 mL). Triphenylphosphine (0.852 g, 3.25 mmol) was added into the solution 
followed by diisopropryl azodicarboxylate (DIAD) (0.64 mL, 3.25 mmol). The resulting yellow 
solution was stirred continuously at rt for 10 min before adding phthalimide (478 mg, 3.25 
mmol). The solution was stirred continuously at rt. After 24 h, the reaction mixture was concd 
and the residue was purified with column chromatography (5% ethyl acetate/hexanes) to give 
3.31 as a white solid (0.639 g, 56%). 3.31.  TLC Rf = 0.53 (10% ethyl acetate/hexanes); 
1H NMR 
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(300 MHz, CDCl3) δ 7.79-7.82 (m, 2H), 7.68-7.71 (m, 2H), 4.62 (s, 1H), 4.61 (s, 1H), 4.49-4.51 
(m, 1H), 2.40-2.59 (m, 1H), 0.78-2.31 (m, 32H). 
 
(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-17-methylene-hexadecahydro-1H-
cyclopenta[a]phenanthren-3-amine (3.32) 
In a 250 mL round bottom flask, steroid 3.31 (0.639 g, 1.53 mmol) was suspended in 77 ml 
MeOH.  Hydrazine (5.8 mL, 119 mmol) was added and the reaction refluxed for one hour.  The 
solvent was evaporated and the residue was dissolved in DCM (150 mL).  The mixture was 
extracted with a NaOH solution (150 mL, 1M) 5 times.  The organic layers were collected, 
combined, dried with sodium sulfate, filtered and concentrated.  Purification was done with 
column chromatography (90:9:1 DCM:MeOH:NH4OH) to give 3.32 as a clear oil (384 mg, 
87%).  3.32. TLC Rf = 0.09 (90:9:1 DCM:MeOH:NH4OH); 
1H NMR (300 MHz, CDCl3) δ 4.61 
(s, 1H), 4.59 (s, 1H), 3.22 (bs, 1H), 2.41-2.71 (m, 3H), 2.20-2.26 (m, 1H), 0.73-1.80 (m, 34H). 
 
(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-17-methylene-hexadecahydro-1H-
cyclopenta[a]phenanthren-3-amine hydrochloride (3.16) 
In a flame dried 50 mL round bottom flask, MeOH (0.11 mL, 2.61 mmol) was suspended in 
ethyl acetate (5 mL) and cooled to 0oC.  Acetyl chloride (0.19 mL, 2.61 mmol) was added slowly 
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and the reaction stirred for 10 minutes.  Amine 3.32 was dissolved in a small amount of ethyl 
acetate and added to the flask.  A white solution formed. The mixture stirred for 30 minutes.  The 
product was filtered and dried under vacuum to give 3.16 as a white solid (0.067 g, 40%).  3.16 
1H NMR (300 MHz, CD3OD) δ 4.59 (s, 1H), 4.57 (s, 1H), 3.49 (bs, 1H), 2.42-2.59 (m, 1H), 
2.10-2.29 (m, 1H), 0.73-2.01 (m, 52H). Anal calcd for C20H34ClN: C, 74.16; H, 10.58; N, 4.32. 
Found: C, 74.17; H, 10.47; N, 4.42. 
 
(3S,5S,8S,9S,10S,13R,14S,17S)-10,13,17-trimethyl-hexadecahydro-1H-
cyclopenta[a]phenanthren-3-ol (3.33) 
Lit. Ref.: Norden, S.; Bender, M.; Rullkötter, J.; Christoffers, J.  Eur. J. Org. Chem. 2011. 4543–
4550.  
In a flame dried 100 mL round bottom flask, steroid 3.30 (0.69 g, 2.4 mmol) was dissolved in 
isopropanol (24 mL).  Palladium on carbon was added to the flask (0.077g, 0.72 mmol) and the 
mixture was put under vacuum.  Hydrogen gas was added after the vacuum was removed and the 
mixture stirred at 65oC for 17 hours.  The mixture was filtered through silica (ether) and 
concentrated to give 3.33 as a white solid (0.629 g, 90%). 3.33.  TLC Rf = 0.53 (25% ethyl 
acetate/hexanes) 1H NMR (300 MHz, CDCl3) δ 3.53-3.62 (m, 1H), 0.72-1.89 (m, 37H), 0.52 (s, 
3H). 
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2-((3R,5S,8S,9S,10S,13R,14S,17S)-10,13,17-trimethyl-hexadecahydro-1H-
cyclopenta[a]phenanthren-3-yl)isoindoline-1,3-dione (3.34) 
In a flame dried 100 mL round bottom flask, alcohol 3.33 (0.629 g, 2.17 mmol) was dissolved in 
dry THF (22 mL). Triphenylphosphine (0.682 g, 2.6 mmol) was added into the solution followed 
by diisopropryl azodicarboxylate (DIAD) (0.52 mL, 2.6 mmol). The resulting yellow solution 
was stirred continuously at rt for 10 min before adding phthalimide (0.383 g, 2.6 mmol). The 
solution was stirred continuously at rt. After 24 h, the reaction mixture was concd and the residue 
was purified with column chromatography (hexanes) to give 3.34 as a white solid (0.445 g, 
49%). 3.34 1H NMR (300 MHz, CDCl3) δ 7.79-7.82 (m, 2H), 7.68-7.70 (m, 2H), 4.47-4.52 (m, 
1H), 0.73-2.1 (m, 36H), 0.54 (s, 3H). 
 
(3R,5S,8S,9S,10S,13R,14S,17S)-10,13,17-trimethyl-hexadecahydro-1H-
cyclopenta[a]phenanthren-3-amine (3.35) 
In a 50 mL round bottom flask, steroid 3.34 (0.445 g, 1.06 mmol) was suspended in 11 ml 
MeOH.  Hydrazine (4 mL, 82.7 mmol) was added and the reaction refluxed for one hour.  The 
solvent was evaporated and the residue was dissolved in DCM (20 mL).  The mixture was 
extracted with a NaOH solution (20 mL, 1M) 5 times.  The organic layers were collected, 
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combined, dried with sodium sulfate, filtered and concentrated.  Purification was done with 
column chromatography (90:9:1 DCM:MeOH:NH4OH) to give 3.35 as a clear oil (215 mg, 
70%).  3.35  1H NMR (300 MHz, CDCl3) δ 3.18 (bs, 1H), 0.71-1.75 (m, 38H), 0.53 (s, 3H). 
 
(3R,5S,8S,9S,10S,13R,14S,17S)-10,13,17-trimethyl-hexadecahydro-1H-
cyclopenta[a]phenanthren-3-amine hydrochloride (3.17) 
Amine 3.35 (0.215 g, 0.743 mmol) was dissolved in diethyl ether (10 mL).  Hydrogen chloride 
(g), resulting from sulfuric acid being added to calcium chloride, was bubbled into the diethyl 
ether solution which resulted in precipitate formation. The suspension was filtered.  The 
precipitate was collected and dried under vacuum to afford amine salt 3.17 (0.184 g, 76%) as a 
white solid.  3.17 1H NMR (300 MHz, CDCl3) δ 8.45 (bs, 3H), 3.60 (bs, 1H) 0.73-1.82 (m, 35H), 
0.53 (s, 3H). Anal calcd for C20H36ClN: C, 73.69; H, 11.13; N, 4.30. Found: C, 73.73; H, 10.81; 
N, 4.26. 
184 
 
Appendix B. 1H AND 13C NMR SPECTRA SUPPLEMENT TO 
CHAPTER 3 
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(3S,5S,8S,9S,10S,13S,14S)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-ol 
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2-((3R,5S,8S,9S,10S,13S,14S)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)isoindoline-1,3-dione
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(3R,5S,8S,9S,10S,13S,14S)-10,13-dimethylhexadecahydro-1H -cyclopenta[a]phenanthren-3-amine
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(3R,5S,8S,9S,10S,13S,14S)-3-iodo-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene
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(3S,5S,8S,9S,10S,13S,14S)-3-azido-10,13-dimethylhexadecahydro-1H -cyclopenta[a]phenanthrene
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(3S,5S,8S,9S,10S,13S,14S)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-amine
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(3S,5S,8S,9S,10S,13S,14S)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-aminium chloride
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N'-((3S,5S,8R,9S,10S,13S,14S)-3-hydroxy-10,13-dimethyldodecahydro-1H-cyclopenta[a]phenanthren-17(2H,10H,14H)-ylidene)-4-methylbenzenesulfonohydrazide
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(3S,5S,8R,9S,10S,13R,14S)-10,13-dimethyl-2,3,4,5,6,7,8,9,10,11,12,13,14,15-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol
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(3R,5S,8R,9S,10S,13R,14S)-3-azido-10,13-dimethyl-2,3,4,5,6,7,8,9,10,11,12,13,14,15-tetradecahydro-1H-cyclopenta[a]phenanthrene
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(3R,5S,8R,9S,10S,13R,14S)-10,13-dimethyl-2,3,4,5,6,7,8,9,10,11,12,13,14,15-tetradecahydro-1H-cyclopenta[a]phenanthren-3-amine
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3.15
(3R,5S,8R,9S,10S,13R,14S)-10,13-dimethyl-2,3,4,5,6,7,8,9,10,11,12,13,14,15-tetradecahydro-1H-
cyclopenta[a]phenanthren-3-aminium chloride
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(3S,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-17-methylenehexadecahydro-1H-cyclopenta[a]phenanthren-3-ol
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3.31
2-((3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-17-methylenehexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)isoindoline-1,3-dione
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(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-17-methylenehexadecahydro-1H-cyclopenta[a]phenanthren-3-amine
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(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-17-methylenehexadecahydro-1H-cyclopenta[a]phenanthren-3-aminium chloride
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(3S,5S,8S,9S,10S,13R,14S,17S)-10,13,17-trimethylhexadecahydro-1H -cyclopenta[a]phenanthren-3-ol
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3.34
2-((3R,5S,8S,9S,10S,13R,14S,17S)-10,13,17-trimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)isoindoline-1,3-dione
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